FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Heiberg, IH
   Jacobsen, BK
   Nesvag, R
   Bramness, JG
   Reichborn-Kjennerud, T
   Naess, O
   Ystrom, E
   Hultman, CM
   Hoye, A
AF Heiberg, Ina H.
   Jacobsen, Bjarne K.
   Nesvag, Ragnar
   Bramness, Jorgen G.
   Reichborn-Kjennerud, Ted
   Naess, Oyvind
   Ystrom, Eivind
   Hultman, Christina M.
   Hoye, Anne
TI Total and cause-specific standardized mortality ratios in patients with
   schizophrenia and/or substance use disorder
SO PLOS ONE
LA English
DT Article
ID SEVERE MENTAL-ILLNESS; ALCOHOL-USE DISORDER; FOLLOW-UP; ALL-CAUSE;
   DRUG-USE; INCREASING MORTALITY; PREMATURE MORTALITY; BIPOLAR DISORDER;
   DUAL DIAGNOSIS; RISK-FACTORS
AB Individuals with schizophrenia or substance use disorder have a substantially increased mortality compared to the general population. Despite a high and probably increasing prevalence of comorbid substance use disorder in people with schizophrenia, the mortality in the comorbid group has been less studied and with contrasting results. We performed a nationwide open cohort study from 2009 to 2015, including all Norwegians aged 20-79 with schizophrenia and/or substance use disorder registered in any specialized health care setting in Norway, a total of 125,744 individuals. There were 12,318 deaths in the cohort, and total, sex-, age- and cause-specific standardized mortality ratios (SMRs) were calculated, comparing the number of deaths in patients with schizophrenia, schizophrenia only, substance use disorder only or a co-occurring diagnosis of schizophrenia and substance use disorder to the number expected if the patients had the age-, sex- and calendar-year specific death rates of the general population. The SMRs were 4.9 (95% CI 4.7-5.1) for all schizophrenia patients, 4.4 (95% CI 4.2-4.6) in patients with schizophrenia without substance use disorder, 6.6 (95% CI 6.5-6.8) in patients with substance use disorder only, and 7.4 (95% CI 7.0-8.2) in patients with both schizophrenia and substance use disorder. The SMRs were elevated in both genders, in all age groups and for all considered causes of death, and most so in the youngest. Approximately 27% of the excess mortality in all patients with schizophrenia was due to the raised mortality in the subgroup with comorbid SUD. The increased mortality in patients with schizophrenia and/or substance use disorder corresponded to more than 10,000 premature deaths, which constituted 84% of all deaths in the cohort. The persistent mortality gap highlights the importance of securing systematic screening and proper access to somatic health care, and a more effective prevention of premature death from external causes in this group.
C1 [Heiberg, Ina H.; Jacobsen, Bjarne K.; Hoye, Anne] Ctr Clin Documentat & Evaluat SKDE, Tromso, Norway.
   [Jacobsen, Bjarne K.] UiT Arctic Univ Norway, Dept Community Med, Tromso, Norway.
   [Nesvag, Ragnar] Oslo Univ Hosp, Nydalen DPS, Oslo, Norway.
   [Bramness, Jorgen G.] Innlandet Hosp Trust, Norwegian Natl Advisory Unit Concurrent Subst Abu, Hamar, Norway.
   [Bramness, Jorgen G.; Hoye, Anne] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Clin Med, Tromso, Norway.
   [Reichborn-Kjennerud, Ted; Ystrom, Eivind; Hoye, Anne] Norwegian Inst Publ Hlth, Dept Mental Disorders, Oslo, Norway.
   [Reichborn-Kjennerud, Ted; Naess, Oyvind] Univ Oslo, Inst Clin Med, Oslo, Norway.
   [Naess, Oyvind] Univ Oslo, Inst Hlth & Soc, Oslo, Norway.
   [Ystrom, Eivind] Univ Oslo, Dept Psychol, Oslo, Norway.
   [Ystrom, Eivind] Univ Oslo, Sch Pharm, PharmacoEpidemiol & Drug Safety Res Grp, Oslo, Norway.
   [Hultman, Christina M.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
   [Hoye, Anne] Univ Hosp North Norway, Div Mental Hlth & Subst Abuse, Tromso, Norway.
RP Heiberg, IH (reprint author), Ctr Clin Documentat & Evaluat SKDE, Tromso, Norway.
EM ina.heiberg@skde.no
RI Ystrom, Eivind/C-4094-2009
OI Ystrom, Eivind/0000-0003-4390-6171; Heiberg, Ina H./0000-0001-7635-5826
FU research grant by the Regional Health Authorities in Northern Norway
   [PFP1236-15]
FX The study is funded by a research grant offered by the Regional Health
   Authorities in Northern Norway. Grant number: PFP1236-15. URL:
   https://helse-nord.no/. The funding sources had no role in the design
   and conduct of the study; collection, management, analysis, and
   interpretation of the data; preparation, review, or approval of the
   manuscript; and decision to submit the manuscript for publication.
CR Adrian M, 2003, SUBST USE MISUSE, V38, P1575, DOI 10.1081/JA-120024230
   ALLGULANDER C, 1989, AM J PUBLIC HEALTH, V79, P1006, DOI 10.2105/AJPH.79.8.1006
   [Anonymous], 2004, INT STAT CLASS DIS R
   Arendt M, 2011, DRUG ALCOHOL DEPEN, V114, P134, DOI 10.1016/j.drugalcdep.2010.09.013
   Batki SL, 2009, SCHIZOPHR RES, V107, P139, DOI 10.1016/j.schres.2008.10.016
   Beary M, 2012, J PSYCHOPHARMACOL, V26, P52, DOI 10.1177/0269881112440512
   Bjorkenstam C, 2014, SCHIZOPHR RES, V157, P1, DOI 10.1016/j.schres.2014.05.010
   Bjorkenstam E, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000778
   Bogdanowicz KM, 2015, DRUG ALCOHOL DEPEN, V148, P85, DOI 10.1016/j.drugalcdep.2014.12.025
   Bretteville-Jensen AL, 2015, DRUG ALCOHOL DEPEN, V147, P89, DOI 10.1016/j.drugalcdep.2014.12.002
   Carstensen B, 2007, SAS MACRO SPLITTING
   Chang CK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019590
   Chang CK, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-77
   Chesney E, 2014, WORLD PSYCHIATRY, V13, P153, DOI 10.1002/wps.20128
   Correll CU, 2015, WORLD PSYCHIATRY, V14, P119, DOI 10.1002/wps.20204
   Dickey B, 2002, PSYCHIATR SERV, V53, P861, DOI 10.1176/appi.ps.53.7.861
   Esse K, 2011, BRAIN BEHAV, V1, P44, DOI 10.1002/brb3.7
   Fazel S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000120
   Frasch K, 2013, INT J SOC PSYCHIATR, V59, P757, DOI 10.1177/0020764012456803
   Gale CR, 2012, ARCH GEN PSYCHIAT, V69, P823, DOI 10.1001/archgenpsychiatry.2011.2000
   Hall W, 2010, ADDICTION, V105, P1332, DOI 10.1111/j.1360-0443.2010.02919.x
   Hansen SS, 2000, ACTA PSYCHIAT SCAND, V102, P432, DOI 10.1034/j.1600-0447.2000.102006432.x
   Hartz SM, 2014, JAMA PSYCHIAT, V71, P248, DOI 10.1001/jamapsychiatry.2013.3726
   Helsedirektoratet [The Norwegian Directorate of Health], 2011, AKT PSYK HELS HELS V
   Helsedirektoratet [The Norwegian Directorate of Health], 2016, AKT AVT 2015
   Helsedirektoratet [The Norwegian Directorate of Health], 2010, AKT SOM SPES 2009
   Helsedirektoratet [The Norwegian Directorate of Health], 2010, AKT AVT 2009
   Hjorthoj C, 2017, LANCET PSYCHIAT, V4, P295, DOI 10.1016/S2215-0366(17)30078-0
   Hjorthoj C, 2015, LANCET PSYCHIAT, V2, P801, DOI 10.1016/S2215-0366(15)00207-2
   Hoye A, 2011, SCHIZOPHR RES, V132, P228, DOI 10.1016/j.schres.2011.07.021
   Hunt GE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001088.pub3
   Jones ME, 1998, AM J EPIDEMIOL, V148, P1012
   Kilbourne AM, 2009, GEN HOSP PSYCHIAT, V31, P555, DOI 10.1016/j.genhosppsych.2009.07.008
   Kiviniemi M, 2010, PSYCHIAT SERV, V61, P272, DOI 10.1176/ps.2010.61.3.272
   Koola MM, 2012, J PSYCHIATR RES, V46, P987, DOI 10.1016/j.jpsychires.2012.04.019
   Large M, 2014, AUST NZ J PSYCHIAT, V48, P418, DOI 10.1177/0004867414525838
   Latalova K, 2014, NEUROPSYCH DIS TREAT, V10, P1925, DOI 10.2147/NDT.S68321
   Laursen TM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067133
   Laursen TM, 2011, J PSYCHIATR RES, V45, P29, DOI 10.1016/j.jpsychires.2010.04.027
   Lawrence D, 2013, BMJ-BRIT MED J, V346, pf2539, DOI DOI 10.1136/BMJ.F2539
   Lawrence D, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-285
   Limosin F, 2007, SCHIZOPHR RES, V94, P23, DOI 10.1016/j.schres.2007.04.031
   Liu NH, 2017, WORLD PSYCHIATRY, V16, P30, DOI 10.1002/wps.20384
   Lumme S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152223
   Maniglio R, 2009, ACTA PSYCHIAT SCAND, V119, P180, DOI 10.1111/j.1600-0447.2008.01300.x
   Manrique-Garcia E, 2012, PSYCHOL MED, V42, P1321, DOI 10.1017/S0033291711002078
   Maraj S, 2010, CLIN CARDIOL, V33, P264, DOI 10.1002/clc.20746
   Mattisson C, 2011, DRUG ALCOHOL DEPEN, V118, P141, DOI 10.1016/j.drugalcdep.2011.03.008
   Mitchell AJ, 2010, J PSYCHOPHARMACOL, V24, P69, DOI 10.1177/1359786810382056
   Murthy P, 2012, CURR OPIN PSYCHIATR, V25, P194, DOI 10.1097/YCO.0b013e328351a3e0
   Nesvag R, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1256-8
   Nesvag R, 2015, SOC PSYCH PSYCH EPID, V50, P1267, DOI 10.1007/s00127-015-1025-2
   Nielsen RE, 2013, SCHIZOPHR RES, V146, P22, DOI 10.1016/j.schres.2013.02.025
   Nordentoft M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055176
   Norwegian Institute of Public Health, 2015, DODSF ETT KJONN ALD
   Nyhlen A, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-122
   Nyhlen A, 2011, J FORENSIC LEG MED, V18, P66, DOI 10.1016/j.jflm.2011.01.003
   Oiesvold T, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-13
   Olfson M, 2015, JAMA PSYCHIAT, V72, P1172, DOI 10.1001/jamapsychiatry.2015.1737
   Onyeka IN, 2014, INT J DRUG POLICY, V25, P1047, DOI 10.1016/j.drugpo.2014.07.008
   Osborn DPJ, 2007, ARCH GEN PSYCHIAT, V64, P242, DOI 10.1001/archpsyc.64.2.242
   Osby U, 2016, EUR J PUBLIC HEALTH, V26, P867, DOI 10.1093/eurpub/ckv245
   Pedersen AG, 2015, TIDSSKR NORSKE LAEGE, V135, P768, DOI 10.4045/tidsskr.14.1065
   Phillips DE, 2014, POPUL HEALTH METR, V12, DOI 10.1186/1478-7954-12-14
   Reininghaus U, 2015, SCHIZOPHRENIA BULL, V41, P664, DOI 10.1093/schbul/sbu138
   Roerecke M, 2013, ADDICTION, V108, P1562, DOI 10.1111/add.12231
   Rose G, 2001, INT J EPIDEMIOL, V30, P427, DOI 10.1093/ije/30.3.427
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Schmidt LM, 2011, SCHIZOPHR RES, V130, P228, DOI 10.1016/j.schres.2011.04.011
   Sorensen HJ, 2005, ACTA PSYCHIAT SCAND, V111, P244, DOI 10.1111/j.1600-0447.2004.00445.x
   Sorensen HJ, 2015, SCHIZOPHR RES, V162, P74, DOI 10.1016/j.schres.2015.01.018
   Speyer H, 2016, WORLD PSYCHIATRY, V15, P155, DOI 10.1002/wps.20318
   Statistics Norway, 2016, FOLK BEF
   Steingrimsson S, 2016, NORD J PSYCHIAT, V70, P161, DOI 10.3109/08039488.2015.1062143
   Volavka J, 2013, PSYCHIAT DANUB, V25, P24
   Wahlbeck K, 2011, BRIT J PSYCHIAT, V199, P453, DOI 10.1192/bjp.bp.110.085100
   Walker ER, 2015, JAMA PSYCHIAT, V72, P334, DOI 10.1001/jamapsychiatry.2014.2502
   Walter F, 2017, JAMA PSYCHIAT, V74, P485, DOI 10.1001/jamapsychiatry.2017.0071
   Westermeyer J, 2006, AM J ADDICTION, V15, P345, DOI 10.1080/10550490600860114
   Westman J, 2015, ACTA PSYCHIAT SCAND, V131, P297, DOI 10.1111/acps.12330
   Wilcox HC, 2004, DRUG ALCOHOL DEPEN, V76, pS11, DOI 10.1016/j.drugalcdep.2004.08.003
   Witt K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055942
NR 82
TC 2
Z9 2
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 23
PY 2018
VL 13
IS 8
AR e0202028
DI 10.1371/journal.pone.0202028
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GR6TZ
UT WOS:000442800100035
PM 30138449
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Ferrer, LM
   Walker, J
   Harrison, C
   Banfield, M
AF Ferrer, Louise M.
   Walker, Jennie
   Harrison, Christopher
   Banfield, Michelle
TI Primary care access for mental illness in Australia: Patterns of access
   to general practice from 2006 to 2016
SO PLOS ONE
LA English
DT Article
ID BIPOLAR DISORDER; GENDER-DIFFERENCES; HEALTH LITERACY;
   PSYCHOLOGICAL-PROBLEMS; PREVALENCE DISORDERS; ANXIETY DISORDERS;
   NATIONAL-SURVEY; SCHIZOPHRENIA; PEOPLE; DEPRESSION
AB General practice has an important role within the Australian healthcare system to provide access to care and effective management of chronic health conditions. However, people with serious mental illness experience challenges associated with service access. The current paper seeks to examine drivers of access to general practice for people with common and serious mental disorders, compared with people who access care for type II diabetes, a common physical health problem managed in general practice. The Bettering the Evaluation and Care of Health (BEACH) programme provides the most comprehensive and objective measurement of general practitioner activity in Australia. Using BEACH data, this study compared general practice encounters for depression, anxiety, bipolar disorder, schizophrenia, and type II diabetes during a 10-year period between 2006 and 2016. Analysis revealed more frequent encounters for depression compared to anxiety, and a higher representation of women in encounters for bipolar disorder compared to men. The relationship between number of encounters and patient age was strongly associated with the life course and mortality characteristics associated with each disorder. The findings highlight specific challenges associated with access to primary care for people with serious mental illness, and suggest areas of focus to improve the ability of these patients to access and navigate the health system.
C1 [Ferrer, Louise M.; Walker, Jennie; Banfield, Michelle] Australian Natl Univ, Ctr Mental Hlth Res, Canberra, ACT, Australia.
   [Harrison, Christopher] Univ Sydney, Menzies Ctr Hlth Policy, Sydney, NSW, Australia.
RP Banfield, M (reprint author), Australian Natl Univ, Ctr Mental Hlth Res, Canberra, ACT, Australia.
EM michelle.banfield@anu.edu.au
FU Australian Research Council Discovery Early Career Researcher Award
   [DE150100637]
FX Author Michelle Banfield is supported by an Australian Research Council
   Discovery Early Career Researcher Award (DE150100637).
CR Afifi M., 2007, SMJ Singapore Medical Journal, V48, P385
   Andrews G, 2001, BRIT J PSYCHIAT, V178, P145, DOI 10.1192/bjp.178.2.145
   Arnold LM, 2003, PSYCHIAT CLIN N AM, V26, P595, DOI 10.1016/S0193-953X(03)00036-4
   Austin PC, 2002, J VASC SURG, V36, P194, DOI 10.1067/mva.2002.125015
   Australian Bureau of Statistics, 2007, NAT SURV MENT HLTH W
   Australian Bureau of Statistics, 2015, NAT HLTH SURV 1 RES
   Australian Bureau of Statistics, 2014, AUSTR AB TORR STRAIT
   Australian Institute of Health and Welfare, 2005, RURAL HLTH SERIES
   Australian Institute of Health and Welfare, 2016, AUSTR BURD DIS STUD
   Australian Institute of Health and Welfare, 2016, MAN AUSTR HAV DIAB
   Australian Medical Association, 2016, POS STAT GEN PRACT P
   Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775
   Britt H, 2014, GEN PRACTICE ACTIVIT
   Britt H, 2015, AUST FAM PHYSICIAN, V44, P411
   Caldwell TM, 2004, AUST NZ J PSYCHIAT, V38, P774, DOI 10.1080/j.1440-1614.2004.01461.x
   Carr VJ, 2002, ACTA PSYCHIAT SCAND, V105, P346, DOI 10.1034/j.1600-0447.2002.1o156.x
   Diflorio A, 2010, INT REV PSYCHIATR, V22, P437, DOI 10.3109/09540261.2010.514601
   Dunstan DW, 2002, DIABETES CARE, V25, P829, DOI 10.2337/diacare.25.5.829
   Family and Community Development Committee, 2012, INQ WORKF PART PEOPL
   Family Medicine Research Centre, 1998, INT CLASS PRIM CAR P
   Family Medicine Research Centre, 1998, ICPC 2 INT CLASS PRI
   Foley DL, 2015, LANCET PSYCHIAT, V2, P1092, DOI 10.1016/S2215-0366(15)00276-X
   Gartrell A, 2005, REPORT TO BEYONDBLUE
   GOLDBERG D, 1995, EPIDEMIOL REV, V17, P182, DOI 10.1093/oxfordjournals.epirev.a036174
   Harris MF, 2007, MED J AUSTRALIA, V187, P104
   Harris MF, 2006, MED J AUSTRALIA, V185, P122
   Harrison CM, 2012, MED J AUSTRALIA, V197, P170, DOI 10.5694/mja12.10555
   Harrison CM, 2004, AUST NZ J PSYCHIAT, V38, P781, DOI 10.1111/j.1440-1614.2004.01462.x
   Hayes LJ, 2006, J PUBLIC HEALTH, V28, P278, DOI 10.1093/pubmed/fdl038
   Hetlevik O, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0719-1
   Highet NJ, 2004, MED J AUSTRALIA, V181, pS47
   Highet NJ, 2002, MED J AUSTRALIA, V176, pS63
   Hunter E, 2007, AUST J RURAL HEALTH, V15, P88, DOI 10.1111/j.1440-1584.2007.00869.x
   Hunter Ernest, 2011, Australas Psychiatry, V19, P434, DOI 10.3109/10398562.2011.583068
   International Diabetes Federation, 2015, IDF DIABETES ATLAS
   Jablensky A, 2000, AUST NZ J PSYCHIAT, V34, P221, DOI 10.1046/j.1440-1614.2000.00728.x
   Jorm AF, 1997, MED J AUSTRALIA, V166, P182, DOI 10.5694/j.1326-5377.1997.tb140071.x
   Jorm AF, 2000, SOC PSYCH PSYCH EPID, V35, P211, DOI 10.1007/s001270050230
   Jorm AF, 2011, AUST NZ J PSYCHIAT, V45, P700, DOI 10.3109/00048674.2011.604302
   Judd FK, 2002, AUST NZ J PSYCHIAT, V36, P104, DOI 10.1046/j.1440-1614.2002.00986.x
   Kuehner C, 2003, ACTA PSYCHIAT SCAND, V108, P163, DOI 10.1034/j.1600-0447.2003.00204.x
   Levesque JF, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-18
   Littlefield L, 2008, CLIN PSYCHOL, P12
   McLean CP, 2011, J PSYCHIATR RES, V45, P1027, DOI 10.1016/j.jpsychires.2011.03.006
   Morgan VA, 2014, PSYCHOL MED, V44, P2163, DOI 10.1017/S0033291713002973
   Morgan VA, 2012, AUST NZ J PSYCHIAT, V46, P735, DOI 10.1177/0004867412449877
   Oud MJT, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-32
   Paulus DJ, 2015, J PUBLIC MENT HEALTH, V14, P94, DOI 10.1108/JPMH-09-2013-0064
   Pillinger T, 2017, JAMA PSYCHIAT, V74, P261, DOI 10.1001/jamapsychiatry.2016.3803
   Pink B, 2008, HLTH WELFARE AUSTR A
   Pink B., 2011, AUSTR STAT GEOGRAPHY
   Pirkis J, 2011, AUST NZ J PSYCHIAT, V45, P726, DOI 10.3109/00048674.2011.594948
   Piterman L, 2010, MED J AUSTRALIA, V193, pS14
   Reavley NJ, 2011, AUST NZ J PSYCHIAT, V45, P947, DOI 10.3109/00048674.2011.621060
   Ride K, 2016, REV DIABETES ABORIGI
   Riordan HJ, 2011, AM HEALTH DRUG BENEF, V4, P292
   Roshanaei-Moghaddam B, 2009, PSYCHIAT SERV, V60, P147, DOI 10.1176/appi.ps.60.2.147
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Vancampfort D, 2016, WORLD PSYCHIATRY, V15, P166, DOI 10.1002/wps.20309
   WHO, 2002, INN CAR CHRON COND B
NR 60
TC 1
Z9 1
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 1
PY 2018
VL 13
IS 6
AR e0198400
DI 10.1371/journal.pone.0198400
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GH8ES
UT WOS:000433900800116
PM 29856836
OA DOAJ Gold
DA 2019-06-25
ER

PT J
AU Lilly, FR
   Culpepper, J
   Stuart, M
   Steinwachs, D
AF Lilly, Flavius Robert
   Culpepper, Joel
   Stuart, Mary
   Steinwachs, Donald
TI Stroke survivors with severe mental illness: Are they at-risk for
   increased non-psychiatric hospitalizations?
SO PLOS ONE
LA English
DT Article
ID OF-VETERANS-AFFAIRS; HEALTH-CARE UTILIZATION; ADMINISTRATIVE DATA;
   MEDICAL-CARE; READMISSION; COMORBIDITY; PREVALENCE; PEOPLE; SYSTEM;
   SCHIZOPHRENIA
AB Background This study examined outcomes for two groups of stroke survivors treated in Veteran Health Administration (VHA) hospitals, those with a severe mental illness (SMI) and those without prior psychiatric diagnoses, to examine risk of non-psychiatric medical hospitalizations over five years after initial stroke.
   Methods This retrospective cohort study included 523 veterans who survived an initial stroke hospitalization in a VHA medical center during fiscal year 2003. The survivors were followed using administrative data documenting inpatient stroke treatment, patient demographics, disease comorbidities, and VHA hospital admissions. Multivariate Poisson regression was used to examine the relationship between patients with and without SMI diagnosis preceding the stroke and their experience with non-psychiatric medical hospitalizations after the stroke.
   Results The study included 100 patients with SMI and 423 without SMI. Unadjusted means for pre-stroke non-psychiatric hospitalizations were higher (p = 0.0004) among SMI patients (1.47 +/- 0.51) compared to those without SMI (1.00 +/- 1.33), a difference which persisted through the first year post-stroke (SMI: 2.33 +/- 2.46; No SMI: 1.74 +/- 1.86; p = 0.0004). Number of non-psychiatric hospitalizations were not significantly different between the two groups after adjustment for patient sociodemographic, comorbidity, length of stay and inpatient stroke treatment characteristics. Antithrombotic medications significantly lowered risk (OR = 0.61; 95% CI: 0.49-0.73) for stroke-related readmission within 30 days of discharge.
   Conclusions No significant differences in medical hospitalizations were present after adjusting for comorbid and sociodemographic characteristics between SMI and non-SMI stroke patients in the five-year follow-up. However, unadjusted results continue to draw attention to disparities, with SMI patients experiencing more non-psychiatric hospitalizations both prior to and up to one year after their initial stroke. Additionally, stroke survivors discharged on antithrombotic medications were at lower risk of re-admission within 30 days suggesting the VHA should continue to focus on effective stroke management irrespective of SMI.
C1 [Lilly, Flavius Robert] Univ Maryland, Grad Sch, Baltimore, MD 21201 USA.
   [Culpepper, Joel] Vet Affairs Maryland Hlth Care Syst, Baltimore, MD USA.
   [Stuart, Mary] Univ Maryland Baltimore Cty, Dept Sociol Anthropol & Hlth Adm & Policy, Baltimore, MD 21228 USA.
   [Steinwachs, Donald] Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA.
RP Lilly, FR (reprint author), Univ Maryland, Grad Sch, Baltimore, MD 21201 USA.
EM Flilly@umaryland.edu
FU VHA
FX The study is a subsidiary investigation of the VHA-funded study to
   translate exercise research into direct patient care delivery for stroke
   survivors. The parent study, "Translational Research for Task-Oriented
   Exercise in Chronic Stroke is designed to develop descriptive and
   comparable data to plan community based demonstration projects using
   Veterans Affairs administrative databases with the broad goal of
   improving stroke patient outcomes.
CR ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284
   Billings J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003352
   Blank MB, 2002, PSYCHIATR SERV, V53, P868, DOI 10.1176/appi.ps.53.7.868
   Borckardt Jeffrey J, 2011, Qual Manag Health Care, V20, P98, DOI 10.1097/QMH.0b013e3182134af0
   Camberg LC, 1997, MED CARE, V35, P756, DOI 10.1097/00005650-199708000-00002
   Culpepper WJ, 2006, J REHABIL RES DEV, V43, P17, DOI 10.1682/JRRD.2004.09.0122
   Curkendall SM, 2004, J CLIN PSYCHIAT, V65, P715
   Daumit GL, 2010, PSYCHIAT RES, V176, P242, DOI 10.1016/j.psychres.2009.01.006
   Daumit GL, 2003, J NERV MENT DIS, V191, P799, DOI 10.1097/01.nmd.0000100923.20188.2d
   De Hert M., 2013, WORLD PSYCHIAT, V10, P52
   Dossa A., 2011, BIOMED CENTRAL HLTH, V11, P1
   Drake R., 2001, COMPREHENSIVE CARE S, p243 
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004
   Epstein AM, 2011, NEW ENGL J MED, V365, P2287, DOI 10.1056/NEJMsa1101942
   Fleishacker W.W., 2008, J CLIN PSYCHIAT 0318, pe1
   Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80
   Halfon P, 2006, MED CARE, V44, P972, DOI 10.1097/01.mlr.0000228002.43688.c2
   Hankin CS, 1999, AM J PSYCHIAT, V156, P1924
   Hendrie HC, 2013, AM J GERIAT PSYCHIAT, V21, P1267, DOI 10.1016/j.jagp.2013.01.056
   Himelhoch S, 2004, AM J PSYCHIAT, V161, P2317, DOI 10.1176/appi.ajp.161.12.2317
   Jha A. K., 2009, NEW ENGL J MED, V348, P2218
   Jia HG, 2007, STROKE, V38, P355, DOI 10.1161/01.STR.0000254457.38901.fb
   Joint Commission, 2008, DIS SPEC CAR CERT PR
   Kashner TM, 1998, MED CARE, V36, P1324, DOI 10.1097/00005650-199809000-00005
   Kennedy BS, 2005, J NATL MED ASSOC, V97, P699
   Kilbourne AM, 2009, PSYCHIAT SERV, V60, P589, DOI 10.1176/appi.ps.60.5.589
   Koepsell TD, 2009, PREV MED, V48, P267, DOI 10.1016/j.ypmed.2009.01.008
   Lester HE, 2005, BRIT MED J, V330, P1122, DOI 10.1136/bmj.38440.418426.8F
   Lichtman JH, 2010, STROKE, V41, P2525, DOI 10.1161/STROKEAHA.110.599159
   Lichtman JH, 2009, STROKE, V40, P3574, DOI 10.1161/STROKEAHA.109.561472
   Lin HC, 2008, SCHIZOPHR RES, V101, P234, DOI 10.1016/j.schres.2007.12.485
   Lin HJ, 2011, NEUROLOGY, V76, P438, DOI 10.1212/WNL.0b013e31820a0cd8
   Martin MY, 2006, J AGING PHYS ACTIV, V14, P392, DOI 10.1123/japa.14.4.392
   Miller DR, 2004, DIABETES CARE, V27, pB10, DOI 10.2337/diacare.27.suppl_2.B10
   Montgomery A. E., 2013, AM J PUBLIC HEALTH, V22, pe01
   O'Day B, 2005, PSYCHIATR REHABIL J, V28, P339, DOI 10.2975/28.2005.339.345
   Parks J, 2006, MORBIDITY MORTALITY, P25
   Peabody JW, 2004, MED CARE, V42, P1066, DOI 10.1097/00005650-200411000-00005
   Petersen LA, 2003, HEALTH SERV RES, V38, P41, DOI 10.1111/1475-6773.00104
   Phelan M, 2001, BRIT MED J, V322, P443, DOI 10.1136/bmj.322.7284.443
   Post EP, 2010, FAM SYST HEALTH, V28, P83, DOI 10.1037/a0020130
   QUERI, QUAL ENH RES IN STRO
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Saravay SM, 1996, AM J PSYCHIAT, V153, P397
   SAS Institute Inc, 2011, BAS SAS 9 3 PROC GUI
   Schneider N. E., 2009, HEALTH QUAL LIFE OUT, V7, P82
   Stahl SM, 2008, ESSENTIAL PSYCHOPHAR
   Sun Y., 2009, VALUE HEALTH, P12
   Tirschwell DL, 2002, STROKE, V33, P2465, DOI 10.1161/01.STR.0000032240.28636.BD
   Trivedi AN, 2011, MED CARE, V49, P76, DOI 10.1097/MLR.0b013e3181f53575
   Viron MJ, 2010, PSYCHOSOMATICS, V51, P458, DOI 10.1176/appi.psy.51.6.458
   Zeiss AM, 2008, J CLIN PSYCHOL MED S, V15, P73, DOI 10.1007/s10880-008-9100-4
NR 52
TC 2
Z9 2
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 11
PY 2017
VL 12
IS 8
AR e0182330
DI 10.1371/journal.pone.0182330
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FD3KL
UT WOS:000407431800013
PM 28800605
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Ribe, AR
   Laurberg, T
   Laursen, TM
   Charles, M
   Vedsted, P
   Vestergaard, M
AF Ribe, Anette Riisgaard
   Laurberg, Tinne
   Laursen, Thomas Munk
   Charles, Morten
   Vedsted, Peter
   Vestergaard, Mogens
TI Ten-Year Mortality after a Breast Cancer Diagnosis in Women with Severe
   Mental Illness: A Danish Population-Based Cohort Study
SO PLOS ONE
LA English
DT Article
ID BIPOLAR AFFECTIVE-DISORDER; SWEDISH NATIONAL COHORT; SCHIZOPHRENIA;
   REGISTER; DENMARK; SURVIVAL; COMORBIDITIES; DISEASE; DEATH; CARE
AB Background
   Breast cancer is the leading cause of cancer death in women worldwide. Nevertheless, it is unknown whether higher mortality after breast cancer contributes to the life-expectancy gap of 15 years in women with severe mental illness (SMI).
   Methods
   We estimated all-cause mortality rate ratios (MRRs) of women with SMI, women with breast cancer and women with both disorders compared to women with neither disorder using data from nationwide registers in Denmark for 1980-2012.
   Results
   The cohort included 2.7 million women, hereof 31,421 women with SMI (12,852 deaths), 104,342 with breast cancer (52,732 deaths), and 1,106 with SMI and breast cancer (656 deaths). Compared to women with neither disorder, the mortality was 118% higher for women with SMI (MRR: 2.18, 95% confidence interval (CI): 2.14-2.22), 144% higher for women with breast cancer (MRR: 2.44, 95% CI: 2.42-2.47) and 327% higher for women with SMI and breast cancer (MRR: 4.27, 95% CI: 3.98-4.57). Among women with both disorders, 15% of deaths could be attributed to interaction. In a sub-cohort of women with breast cancer, the ten-year all-cause-mortality was 59% higher after taking tumor stage into account (MRR: 1.59, 95% CI: 1.47-1.72) for women with versus without SMI.
   Conclusions
   The mortality among women with SMI and breast cancer was markedly increased. More information is needed to determine which factors might explain this excess mortality, such as differences between women with and without SMI in access to diagnostics, provision of care for breast cancer or physical comorbidity, health-seeking-behavior, and adherence to treatment.
C1 [Ribe, Anette Riisgaard; Vedsted, Peter; Vestergaard, Mogens] Aarhus Univ, Dept Publ Hlth, Res Unit Gen Practice, Bartholins Alle 2, DK-8000 Aarhus C, Denmark.
   [Ribe, Anette Riisgaard; Charles, Morten; Vestergaard, Mogens] Aarhus Univ, Dept Publ Hlth, Sect Gen Med Practice, Bartholins Alle 2, DK-8000 Aarhus C, Denmark.
   [Laurberg, Tinne] Aarhus Univ Hosp, Dept Expt Clin Oncol, DK-8000 Aarhus C, Denmark.
   [Laursen, Thomas Munk] Aarhus Univ, Dept Econ & Business Econ, Natl Ctr Register Based Res, Fuglesangs Alle 4, DK-8210 Aarhus V, Denmark.
RP Ribe, AR (reprint author), Aarhus Univ, Dept Publ Hlth, Res Unit Gen Practice, Bartholins Alle 2, DK-8000 Aarhus C, Denmark.; Ribe, AR (reprint author), Aarhus Univ, Dept Publ Hlth, Sect Gen Med Practice, Bartholins Alle 2, DK-8000 Aarhus C, Denmark.
EM ar@feap.dk
RI Vedsted, Peter/C-2583-2008
OI Vedsted, Peter/0000-0003-2113-5599; Laursen, Thomas
   Munk/0000-0001-6934-1784
FU Lundbeck Foundation [R155-2012-11280]; Novo Nordisk Fonden
   [NNF14OC0008981]
FX This study was supported by an unrestricted grant from the Lundbeck
   Foundation (grant number: R155-2012-11280)
   http://www.lundbeckfoundation.com/. The funders had no role in the study
   design, data collection or analysis, decision to publish, or prepation
   of the manuscript.
CR Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9
   Brown S, 1999, PSYCHOL MED, V29, P697, DOI 10.1017/S0033291798008186
   Carlsen K, 2008, EUR J CANCER, V44, P1996, DOI 10.1016/j.ejca.2008.06.027
   Carstensen B, 2011, SCAND J PUBLIC HEALT, V39, P58, DOI 10.1177/1403494811404278
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Crump C, 2013, JAMA PSYCHIAT, V70, P931, DOI 10.1001/jamapsychiatry.2013.1394
   Crump C, 2013, AM J PSYCHIAT, V170, P324, DOI 10.1176/appi.ajp.2012.12050599
   Dalton SO, 2007, INT J CANCER, V121, P2524, DOI 10.1002/ijc.22979
   Druss BG, 2000, JAMA-J AM MED ASSOC, V283, P506, DOI 10.1001/jama.283.4.506
   Ewertz M, 2011, J CLIN ONCOL, V29, P25, DOI 10.1200/JCO.2010.29.7614
   Gjerstorff ML, 2011, SCAND J PUBLIC HEALT, V39, P42, DOI 10.1177/1403494810393562
   Greenland S., 2008, MODERN EPIDEMIOLOGY, P71
   Helweg-Larsen K, 2011, SCAND J PUBLIC HEALT, V39, P26, DOI 10.1177/1403494811399958
   Holmes MD, 2005, JAMA-J AM MED ASSOC, V293, P2479, DOI 10.1001/jama.293.20.2479
   Irwin KE, 2014, CANCER-AM CANCER SOC, V120, P323, DOI 10.1002/cncr.28431
   Jakobsen KD, 2005, NORD J PSYCHIAT, V59, P209, DOI 10.1080/08039480510027698
   Jensen AR, 2002, EUR J CANCER PREV, V11, P359, DOI 10.1097/00008469-200208000-00007
   Jeste DV, 1996, SCHIZOPHRENIA BULL, V22, P413, DOI 10.1093/schbul/22.3.413
   Laursen TM, 2007, J CLIN PSYCHIAT, V68, P899, DOI 10.4088/JCP.v68n0612
   Laursen TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024597
   Laursen TM, 2011, SCHIZOPHR RES, V131, P101, DOI 10.1016/j.schres.2011.06.008
   Laursen TM, 2011, J PSYCHIATR RES, V45, P29, DOI 10.1016/j.jpsychires.2010.04.027
   Laursen TM, 2009, ARCH GEN PSYCHIAT, V66, P713, DOI 10.1001/archgenpsychiatry.2009.61
   Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482
   Mors O, 2011, SCAND J PUBLIC HEALT, V39, P54, DOI 10.1177/1403494810395825
   Munk-Jorgensen P, 2000, ACTA PSYCHIAT SCAND, V102, P96, DOI 10.1034/j.1600-0447.2000.00019.x
   Ording Anne Gulbech, 2012, Clin Epidemiol, V4 Suppl 2, P11, DOI 10.2147/CLEP.S31574
   Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965
   Ribe AR, 2015, AM J PSYCHIAT, V172, P776, DOI 10.1176/appi.ajp.2015.14091100
   Ribe AR, 2014, PSYCHOL MED, P1
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Sharpe M, 2014, LANCET, V384, P1099, DOI 10.1016/S0140-6736(14)61231-9
   Smith DJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-263
   Smith DJ, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002808
   Sogaard Mette, 2013, Clin Epidemiol, V5, P3, DOI 10.2147/CLEP.S47150
   STERLING TD, 1992, EPIDEMIOLOGY, V3, P11, DOI 10.1097/00001648-199201000-00004
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tran E, 2009, CANCER-AM CANCER SOC, V115, P3555, DOI 10.1002/cncr.24383
   Yancik R, 2001, JAMA-J AM MED ASSOC, V285, P885, DOI 10.1001/jama.285.7.885
NR 39
TC 6
Z9 6
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 27
PY 2016
VL 11
IS 7
AR e0158013
DI 10.1371/journal.pone.0158013
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT5IJ
UT WOS:000381515900005
PM 27462907
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Lumme, S
   Pirkola, S
   Manderbacka, K
   Keskimaki, I
AF Lumme, Sonja
   Pirkola, Sami
   Manderbacka, Kristiina
   Keskimaki, Ilmo
TI Excess Mortality in Patients with Severe Mental Disorders in 1996-2010
   in Finland
SO PLOS ONE
LA English
DT Article
ID ISCHEMIC-HEART-DISEASE; AVOIDABLE MORTALITY; PSYCHIATRIC-PATIENTS;
   PHYSICAL ILLNESS; SUBSTANCE USE; HEALTH; SCHIZOPHRENIA; REGISTER;
   QUALITY; PEOPLE
AB Unselected population-based nationwide studies on the excess mortality of individuals with severe mental disorders are scarce with regard to several important causes of death. Using comprehensive register data, we set out to examine excess mortality and its trends among patients with severe mental disorders compared to the total population. Patients aged 2574 and hospitalised with severe mental disorders in 1990-2010 in Finland were identified using the national hospital discharge register and linked individually to population register data on mortality and demographics. We studied mortality in the period 1996-2010 among patients with psychotic disorders, psychoactive substance use disorders, and mood disorders by several causes of death. In addition to all-cause mortality, we examined mortality amenable to health care interventions, ischaemic heart disease mortality, disease mortality, and alcohol-related mortality. Patients with severe mental disorders had a clearly higher mortality rate than the total population throughout the study period regardless of cause of death, with the exception of alcohol-related mortality among male patients with psychotic disorders without comorbidity with substance use disorders. The all-cause mortality rate ratio of patients with psychotic disorders compared to the total population was 3.48 (95% confidence interval 2.98-4.06) among men and 3.75 (95% CI 3.08-4.55) among women in the period 2008-10. The corresponding rate ratio of patients with psychoactive substance use disorders was 5.33 (95% CI 4.87-5.82) among men and 7.54 (95% CI 6.30-9.03) among women. Overall, the mortality of the total population and patients with severe mental disorders decreased between 1996 and 2010. However, the mortality rate ratio of patients with psychotic disorders and patients with psychoactive substance use disorders compared to the total population increased in general during the study period. Exceptions were alcohol-related mortality among patients with psychoactive substance use disorders and female patients with psychotic disorders, as well as amenable mortality among male patients with psychotic disorders. The mortality rate ratio of persons with mood disorders compared to the total population decreased. The markedly high mortality amenable to health care intervention among patients with severe mental disorders found in our study suggests indirectly that they may receive poorer quality somatic care. The results highlight the challenges in co-ordinating mental and somatic health services.
C1 [Lumme, Sonja; Manderbacka, Kristiina; Keskimaki, Ilmo] Natl Inst Hlth & Welf, Dept Hlth & Social Care Syst, Hlth & Social Syst Res Unit, Helsinki, Finland.
   [Pirkola, Sami; Keskimaki, Ilmo] Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland.
RP Lumme, S (reprint author), Natl Inst Hlth & Welf, Dept Hlth & Social Care Syst, Hlth & Social Syst Res Unit, Helsinki, Finland.
EM sonja.lumme@thl.fi
FU Academy of Finland [277939]
FX This work was financially supported by the Academy of Finland (grant
   number 277939). IK. http://www.aka.fi/. The funder had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ajetunmobi O, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002768
   Bjorkenstam E, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000778
   Brown S, 2000, BRIT J PSYCHIAT, V177, P212, DOI 10.1192/bjp.177.3.212
   Clayton D, 1993, STAT MODELS EPIDEMIO
   Corten P h, 1988, Acta Psychiatr Belg, V88, P349
   De Hert M, 2011, WORLD PSYCHIATRY, V10, P52
   Gissler M, 2004, NORSK EPIDEMIOLOGI, V14, P113
   Hamer M, 2008, ARCH INTERN MED, V168, P2474, DOI 10.1001/archinte.168.22.2474
   Havassy BE, 2004, AM J PSYCHIAT, V161, P139, DOI 10.1176/appi.ajp.161.1.139
   Hoang U, 2013, ACTA PSYCHIAT SCAND, V127, P195, DOI 10.1111/acps.12045
   Kisely S, 2009, BRIT J PSYCHIAT, V195, P545, DOI 10.1192/bjp.bp.109.067082
   Kisely S, 2008, CAN J PSYCHIAT, V53, P753, DOI 10.1177/070674370805301107
   Lahti RA, 2001, FORENSIC SCI INT, V115, P15, DOI 10.1016/S0379-0738(00)00300-5
   Lawrence D, 2010, J PSYCHOPHARMACOL, V24, P61, DOI 10.1177/1359786810382058
   Lawrence DM, 2003, BRIT J PSYCHIAT, V182, P31, DOI 10.1192/bjp.182.1.31
   Leucht S, 2007, ACTA PSYCHIAT SCAND, V116, P317, DOI 10.1111/j.1600-0447.2007.01095.x
   Manderbacka K, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000831
   Maynard C, 2004, ADM POLICY MENT HLTH, V31, P339
   Nolte E, 2004, DOES HEALTHCARE SAVE
   Nolte E, 2008, HEALTH AFFAIR, V27, P58, DOI 10.1377/hlthaff.27.1.58
   Page A, 2006, AUSTR NZ ATLAS AVOID
   Penninx BWJH, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-129
   Pirkola S, 2007, PSYCHIAT SERV, V58, P221, DOI 10.1176/appi.ps.58.2.221
   Rasanen S, 2005, NORD J PSYCHIAT, V59, P103, DOI 10.1080/08039480510022909
   REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511
   RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Sund R, 2012, SCAND J PUBLIC HEALT, V40, P505, DOI 10.1177/1403494812456637
   Tidemalm Dag, 2008, Clin Pract Epidemiol Ment Health, V4, P23, DOI 10.1186/1745-0179-4-23
   Vuorenkoski L, 2008, HLTH SYSTEMS TRANSIT, V10, P1
   Wahlbeck K, 2011, BRIT J PSYCHIAT, V199, P453, DOI 10.1192/bjp.bp.110.085100
   Weitoft GR, 1998, SOC PSYCH PSYCH EPID, V33, P430
   Westman J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002373
NR 33
TC 14
Z9 14
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 24
PY 2016
VL 11
IS 3
AR e0152223
DI 10.1371/journal.pone.0152223
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DH3SV
UT WOS:000372708000115
PM 27010534
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Hsu, WY
   Lin, CL
   Kao, CH
AF Hsu, Wen-Yu
   Lin, Cheng-Li
   Kao, Chia-Hung
TI A Population-Based Cohort Study on Peripheral Arterial Disease in
   Patients with Schizophrenia
SO PLOS ONE
LA English
DT Article
ID METABOLIC SYNDROME; DIABETES-MELLITUS; OCCLUSIVE DISEASE; PREVALENCE;
   MORTALITY; RISK; PEOPLE; ANTIPSYCHOTICS; HYPERLIPIDEMIA; METAANALYSIS
AB Purpose
   Peripheral arterial disease (PAD) is considered the leading cause of atherosclerotic cardiovascular morbidity. Several risk factors of PAD have been observed in patients with schizophrenia. Therefore, we hypothesize that the incidence of PAD is higher in the schizophrenia population than in the general population.
   Methods
   The patients in this population-based cohort study were selected from the Taiwanese National Health Insurance Research Database on the basis of the claims data from 2000 to 2011. We compared the incidence of PAD between schizophrenia and nonschizophrenia cohorts. Cox proportional hazard regression models were employed for analyzing the risk of PAD after adjustment for sex, age, and comorbidities.
   Results
   The adjusted hazard ratio (HR) for PAD in the schizophrenia cohort was 1.26-fold higher than that in the nonschizophrenia cohort. Furthermore, patients with schizophrenia using atypical antipsychotics exhibited a high adjusted HR for PAD.
   Conclusion
   Compared with the general population, the risk of PAD is higher among patients with schizophrenia. Early diagnosis and intervention can mitigate complications resulting from cardiovascular diseases and lower mortality.
C1 [Hsu, Wen-Yu] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan.
   [Hsu, Wen-Yu] Lutung Christian Hosp, Dept Psychiat, Lukang, Taiwan.
   [Hsu, Wen-Yu] Chung Shan Med Univ, Sch Med, Dept Psychiat, Taichung, Taiwan.
   [Lin, Cheng-Li] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan.
   [Lin, Cheng-Li] China Med Univ, Coll Med, Taichung, Taiwan.
   [Kao, Chia-Hung] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan.
   [Kao, Chia-Hung] China Med Univ, Coll Med, Sch Med, Taichung, Taiwan.
   [Kao, Chia-Hung] China Med Univ Hosp, Dept Nucl Med, Taichung, Taiwan.
   [Kao, Chia-Hung] China Med Univ Hosp, PET Ctr, Taichung, Taiwan.
RP Kao, CH (reprint author), China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan.; Kao, CH (reprint author), China Med Univ, Coll Med, Sch Med, Taichung, Taiwan.; Kao, CH (reprint author), China Med Univ Hosp, Dept Nucl Med, Taichung, Taiwan.; Kao, CH (reprint author), China Med Univ Hosp, PET Ctr, Taichung, Taiwan.
EM d10040@mail.cmuh.org.tw
FU Taiwan Ministry of Health and Welfare Clinical Trial and Research Center
   of Excellence [MOHW104-TDU-B-212-113002]; China Medical University
   Hospital, Academia Sinica Taiwan Biobank, Stroke Biosignature Project
   [BM104010092]; NRPB Stroke Clinical Trial Consortium [MOST
   103-2325-B-039 -006]; Tseng-Lien Lin Foundation, Taichung, Taiwan;
   Taiwan Brain Disease Foundation, Taipei, Taiwan; Katsuzo and Kiyo
   Aoshima Memorial Funds, Japan; CMU under the Aim for Top University Plan
   of the Ministry of Education, Taiwan
FX This study is supported in part by Taiwan Ministry of Health and Welfare
   Clinical Trial and Research Center of Excellence
   (MOHW104-TDU-B-212-113002); China Medical University Hospital, Academia
   Sinica Taiwan Biobank, Stroke Biosignature Project (BM104010092); NRPB
   Stroke Clinical Trial Consortium (MOST 103-2325-B-039 -006); Tseng-Lien
   Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation,
   Taipei, Taiwan; Katsuzo and Kiyo Aoshima Memorial Funds, Japan; and CMU
   under the Aim for Top University Plan of the Ministry of Education,
   Taiwan. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. No
   additional external funding was received for this study.
CR Allison MA, 2007, AM J PREV MED, V32, P328, DOI 10.1016/j.amepre.2006.12.010
   [Anonymous], 2004, J CLIN PSYCHIAT, V65, P267
   Bai YM, 2013, J AFFECT DISORDERS, V150, P57, DOI 10.1016/j.jad.2013.02.019
   Beratis S, 2001, COMPR PSYCHIAT, V42, P393, DOI 10.1053/comp.2001.26273
   Burghardt KJ, 2014, J PSYCHOPHARMACOL, V28, P349, DOI 10.1177/0269881113516200
   Cacoub Patrice P, 2009, Atherosclerosis, V204, pe86, DOI 10.1016/j.atherosclerosis.2008.10.023
   Carman TL, 2000, AM FAM PHYSICIAN, V61, P1027
   Ciccone MM, 2014, J DIABETES METAB, V5, DOI 10.4172/2155-6156.1000364
   de Leon J, 2005, SCHIZOPHR RES, V76, P135, DOI 10.1016/j.schres.2005.02.010
   Ellingrod VL, 2011, SCHIZOPHR RES, V130, P20, DOI 10.1016/j.schres.2011.03.031
   Fowkes FGR, 2008, JAMA-J AM MED ASSOC, V300, P197, DOI 10.1001/jama.300.2.197
   Fowkes FGR, 2013, LANCET, V382, P1329, DOI 10.1016/S0140-6736(13)61249-0
   Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526
   Hooi JD, 2004, J CLIN EPIDEMIOL, V57, P294, DOI 10.1016/j.jclinepi.2003.09.003
   Hooi JD, 2001, AM J EPIDEMIOL, V153, P666, DOI 10.1093/aje/153.7.666
   Hsieh PH, 2013, J CLIN PSYCHOPHARM, V33, P299, DOI 10.1097/JCP.0b013e3182900dfe
   Hsu JH, 2012, GEN HOSP PSYCHIAT, V34, P360, DOI 10.1016/j.genhosppsych.2012.02.004
   Israel AK, 2011, SCHIZOPHR RES, V128, P44, DOI 10.1016/j.schres.2011.02.007
   Leucht S, 2007, ACTA PSYCHIAT SCAND, V116, P317, DOI 10.1111/j.1600-0447.2007.01095.x
   McCreadie RG, 2002, BRIT J PSYCHIAT, V181, P321, DOI 10.1192/bjp.181.4.321
   McEvoy JP, 2005, SCHIZOPHR RES, V80, P19, DOI 10.1016/j.schres.2005.07.014
   Mitchell AJ, 2013, SCHIZOPHRENIA BULL, V39, P306, DOI 10.1093/schbul/sbr148
   Osborn DPJ, 2007, ARCH GEN PSYCHIAT, V64, P242, DOI 10.1001/archpsyc.64.2.242
   Pande RL, 2011, CIRCULATION, V124, P17, DOI 10.1161/CIRCULATIONAHA.110.003954
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Shammas NW, 2007, VASC HEALTH RISK MAN, V3, P229, DOI 10.2147/vhrm.2007.3.2.229
   Sigvant B, 2007, J VASC SURG, V45, P1185, DOI 10.1016/j.jvs.2007.02.004
   Stubbs B, 2015, ACTA PSYCHIAT SCAND, V132, P144, DOI 10.1111/acps.12439
   Vancampfort D, 2012, ACTA PSYCHIAT SCAND, V125, P352, DOI 10.1111/j.1600-0447.2011.01814.x
NR 29
TC 1
Z9 1
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 12
PY 2016
VL 11
IS 2
AR e0148759
DI 10.1371/journal.pone.0148759
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DD6SI
UT WOS:000370054100053
PM 26871697
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Fang, YX
   He, M
   Lin, JY
   Ma, KJ
   Zhao, H
   Hong, Z
   Li, BX
AF Fang, You-Xin
   He, Meng
   Lin, Jun-Yi
   Ma, Kai-Jun
   Zhao, Hai
   Hong, Zhen
   Li, Bei-Xu
TI Suicidal Drownings with Psychiatric Disorders in Shanghai: A
   Retrospective Study from 2010.1 to 2014.6
SO PLOS ONE
LA English
DT Article
ID SEASONAL-VARIATION; SCHIZOPHRENIA; RISK; MORTALITY; PSYCHOSIS; AUTOPSY;
   CHINA
AB Psychiatric disorders exhibited in 13% suicidal drownings in Southwestern Croatia and 63% in Milan, but in China is unknown. This study is committed to outline the feature of a suicidal drowning with psychiatric disorder, show mental status and reveal key factor to high incidence in China. Immersed corpses were handled by SPSBMPH in its jurisdiction range. Half of immersed corpses were suicidal, and nearly half of suicides had psychiatric disorders. 104 suicidal drownings with psychiatric disorders cases from 2010.1 to 2014.6 were reviewed (21.5% of all immersed corpses, 42.1% of suicides). Most victims clothed normally, and only 2 fastened attached weights. Male victims were more and younger than female. Psycho were prone to commit suicidal drowning in warm and hot season. Psycho were prone to choose familiar area to commit suicide, 45 decedents were found in their familiar areas. Suicidal drowings were occult without suicide attempts, suicide note or abnormal clothing, but showed abnormal mental or behavior changes prior to suicide. The three leading psychiatric disorders were depression (33.7%), depression status (30.8%) and schizophrenia (20.2%). Only 44.2% decedents had visited psychiatric disorder specialist, and merely less than 10% patients could adhere to regular medication. No regular medication on psychiatric disorder was the key factor contributing to high incidence of suicide in psycho. Professional psychiatric and psychological intervention should be taken as soon as possible when they had psychiatric symptoms or suffered misfortune. Guardians should be alert to patients' abnormality to detect their suicidal ideation and intervene, especially in warm season.
C1 [Fang, You-Xin; Hong, Zhen] Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai 200433, Peoples R China.
   [He, Meng; Lin, Jun-Yi; Li, Bei-Xu] Fudan Univ, Sch Basic Med Sci, Dept Forens Med, Shanghai 200433, Peoples R China.
   [Ma, Kai-Jun] Shanghai Publ Secur Bur, Inst Forens Sci, Shanghai Key Lab Crime Scene Evidence, Shanghai, Peoples R China.
   [Zhao, Hai] Shanghai Publ Secur Bur, Shanghai Publ Secur Bur Marine Police Headquarter, Shanghai, Peoples R China.
RP Li, BX (reprint author), Fudan Univ, Sch Basic Med Sci, Dept Forens Med, Shanghai 200433, Peoples R China.
EM libeixu@gmail.com
FU Funds for Youth in Department of Forensic Medicine, School of Basic
   Medical Sciences, Fudan University [FY2014-04]
FX This study is supported by Funds for Youth in Department of Forensic
   Medicine, School of Basic Medical Sciences, Fudan University
   (FY2014-04). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Ajdacic-Gross V, 2003, SOC SCI MED, V57, P1173, DOI 10.1016/S0277-9536(02)00493-8
   Bando DH, 2014, CRISIS, V35, P5, DOI 10.1027/0227-5910/a000222
   Brown S, 1997, BRIT J PSYCHIAT, V171, P502, DOI 10.1192/bjp.171.6.502
   CALDWELL CB, 1990, SCHIZOPHRENIA BULL, V16, P571, DOI 10.1093/schbul/16.4.571
   Cantor CH, 2000, PSYCHOPATHOLOGY, V33, P303, DOI 10.1159/000029162
   Cavanagh JTO, 2003, PSYCHOL MED, V33, P395, DOI 10.1017/S0033291702006943
   Cheung YB, 2006, J AFFECT DISORDERS, V90, P193, DOI 10.1016/j.jad.2005.11.018
   Dutta R, 2012, PSYCHOL MED, V42, P1649, DOI 10.1017/S0033291711002807
   Grjibovski AM, 2013, MED LITH, V49, P379
   Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205
   Hawton K, 2005, BRIT J PSYCHIAT, V187, P9, DOI 10.1192/bjp.187.1.9
   Hawton K, 2003, PSYCHOL MED, V33, P987, DOI 10.1017/S0033291703007943
   He M, 2014, AM J FOREN MED PATH, V35, P218, DOI 10.1097/PAF.0000000000000115
   Jeon HJ, 2014, J AFFECT DISORDERS, V166, P206, DOI 10.1016/j.jad.2014.05.010
   Law CK, 2013, INT J ENV RES PUB HE, V10, P2825, DOI 10.3390/ijerph10072825
   Lopez-Morinigo JD, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0213-z
   MILES CP, 1977, J NERV MENT DIS, V164, P231, DOI 10.1097/00005053-197704000-00002
   Muccino E, 2015, INT J LEGAL MED, V129, P777, DOI 10.1007/s00414-014-1115-9
   Palmer BA, 2005, ARCH GEN PSYCHIAT, V62, P247, DOI 10.1001/archpsyc.62.3.247
   Phillips MR, 2002, LANCET, V359, P835, DOI 10.1016/S0140-6736(02)07954-0
   Ran MS, 2003, ACTA PSYCHIAT SCAND, V107, P430, DOI 10.1034/j.1600-0447.2003.02014.x
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Shibre T, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-150
   Stemberga V, 2010, AM J FOREN MED PATH, V31, P52, DOI 10.1097/PAF.0b013e3181c215c8
NR 24
TC 1
Z9 1
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 27
PY 2015
VL 10
IS 4
AR e0121050
DI 10.1371/journal.pone.0121050
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG9SB
UT WOS:000353659100005
PM 25915853
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Bak, M
   Fransen, A
   Janssen, J
   van Os, J
   Drukker, M
AF Bak, Maarten
   Fransen, Annemarie
   Janssen, Jouke
   van Os, Jim
   Drukker, Marjan
TI Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PLACEBO-CONTROLLED TRIAL; BIPOLAR-I-DISORDER; PALIPERIDONE
   EXTENDED-RELEASE; BORDERLINE PERSONALITY-DISORDER; ACTING INJECTABLE
   RISPERIDONE; DOUBLE-BLIND TRIAL; TREATMENT-RESISTANT SCHIZOPHRENIA;
   OPEN-LABEL TRIAL; POSTTRAUMATIC-STRESS-DISORDER; ORALLY DISINTEGRATING
   TABLETS
AB Introduction: Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses generally are restricted to second generation antipsychotics (SGA) and do not stratify for duration of AP use. It is hypothesised that patients gain more weight if duration of AP use is longer.
   Method: A meta-analysis was conducted of clinical trials of AP that reported weight change. Outcome measures were body weight change, change in BMI and clinically relevant weight change (7% weight gain or loss). Duration of AP-use was stratified as follows: <= 6 weeks, 6-16 weeks, 16-38 weeks and >38 weeks. Forest plots stratified by AP as well as by duration of use were generated and results were summarised in figures.
   Results: 307 articles met inclusion criteria. The majority were AP switch studies. Almost all AP showed a degree of weight gain after prolonged use, except for amisulpride, aripiprazole and ziprasidone, for which prolonged exposure resulted in negligible weight change. The level of weight gain per AP varied from discrete to severe. Contrary to expectations, switch of AP did not result in weight loss for amisulpride, aripiprazole or ziprasidone. In AP-naive patients, weight gain was much more pronounced for all AP.
   Conclusion: Given prolonged exposure, virtually all AP are associated with weight gain. The rational of switching AP to achieve weight reduction may be overrated. In AP-naive patients, weight gain is more pronounced.
C1 [Bak, Maarten; Janssen, Jouke; van Os, Jim; Drukker, Marjan] Maastricht Univ, Med Ctr, South Limburg Mental Hlth Res & Teaching Network, EURON, Maastricht, Netherlands.
   [Fransen, Annemarie] Maxima Med Ctr, Dep Gynaecol, Veldhoven, Netherlands.
   [van Os, Jim] Kings Coll London, Kings Hlth Partners, Dept Psychosis Studies, Inst Psychiat, London, England.
RP Bak, M (reprint author), Maastricht Univ, Med Ctr, South Limburg Mental Hlth Res & Teaching Network, EURON, Maastricht, Netherlands.
EM m.bak@maastrichtuniversity.nl
CR Addington DEN, 2004, J CLIN PSYCHIAT, V65, P1624, DOI 10.4088/JCP.v65n1207
   Addington DE, 2009, CAN J PSYCHIAT, V54, P46, DOI 10.1177/070674370905400108
   Ader M, 2008, J PSYCHIATR RES, V42, P1076, DOI 10.1016/j.jpsychires.2008.01.004
   Allison DB, 2009, AM J PREV MED, V36, P341, DOI 10.1016/j.amepre.2008.11.020
   Allison DB, 1999, AM J PSYCHIAT, V156, P1686
   Alptekin K, 2009, INT CLIN PSYCHOPHARM, V24, P229, DOI 10.1097/YIC.0b013e32832c2624
   Alvarez E, 2006, J CLIN PSYCHOPHARM, V26, P238, DOI 10.1097/01.jcp.0000222513.63767.de
   Alvarez-Jimenez M, 2008, BRIT J PSYCHIAT, V193, P101, DOI 10.1192/bjp.bp.107.042853
   Alvarez-Jimenez M, 2008, CNS DRUGS, V22, P547, DOI 10.2165/00023210-200822070-00002
   Apiquian R, 2005, NEUROPSYCHOPHARMACOL, V30, P2236, DOI 10.1038/sj.npp.1300796
   Apiquian R, 2003, SCHIZOPHR RES, V59, P35, DOI 10.1016/S0920-9964(01)00342-5
   Appelberg B, 2004, EUR PSYCHIAT, V19, P516, DOI 10.1016/j.eurpsy.2004.06.035
   Arranz B, 2007, HUM PSYCHOPHARM CLIN, V22, P11, DOI 10.1002/hup.819
   Ascher-Svanum Haya, 2005, J Psychopharmacol, V19, P110, DOI 10.1177/0269881105058978
   Ascher-Svanum H, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-3
   Azorin JM, 2006, INT CLIN PSYCHOPHARM, V21, P49, DOI 10.1097/01.yic.0000177020.26311.a7
   Azorin JM, 2001, AM J PSYCHIAT, V158, P1305, DOI 10.1176/appi.ajp.158.8.1305
   Baldessarini RJ, 2003, J CLIN PSYCHOPHARM, V23, P370, DOI 10.1097/01.jcp.0000085410.08426.9a
   Baptista T, 2007, INT CLIN PSYCHOPHARM, V22, P205, DOI 10.1097/YIC.0b013e328080ca44
   Baptista T, 2007, SCHIZOPHR RES, V89, P350, DOI 10.1016/j.schres.2006.08.020
   Barak Y, 2002, PROG NEURO-PSYCHOPH, V26, P1199, DOI 10.1016/S0278-5846(01)00322-0
   Barak Y, 2004, INT J NEUROPSYCHOPH, V7, P165, DOI 10.1017/S1461145703004048
   Barak Y, 2002, J CLIN PSYCHIAT, V63, P117, DOI 10.4088/JCP.v63n0205
   Basson BR, 2001, J CLIN PSYCHIAT, V62, P231, DOI 10.4088/JCP.v62n0404
   Baymiller SP, 2002, CLIN NEUROPHARMACOL, V25, P202, DOI 10.1097/01.WNF.0000016460.86853.33
   Beary M, 2012, J PSYCHOPHARMACOL, V26, P52, DOI 10.1177/0269881112440512
   Beasley CM, 2003, J CLIN PSYCHOPHARM, V23, P582, DOI 10.1097/01.jcp.0000095348.32154.ec
   Bhowmick S, 2010, AUST NZ J PSYCHIAT, V44, P237, DOI 10.3109/00048670903487134
   Bitter I, 2004, PROG NEURO-PSYCHOPH, V28, P173, DOI 10.1016/j.pnpbp.2003.09.033
   Bitter I, 2010, WORLD J BIOL PSYCHIA, V11, P894, DOI 10.3109/15622975.2010.505663
   Blonde L, 2008, J CLIN PSYCHIAT, V69, P741, DOI 10.4088/JCP.v69n0507
   Bobes J, 2003, SCHIZOPHR RES, V62, P77, DOI 10.1016/S0920-9964(02)00431-0
   Bobo WV, 2011, ANN CLIN PSYCHIATRY, V23, P193
   Bobo WV, 2010, HUM PSYCHOPHARM CLIN, V25, P30, DOI 10.1002/hup.1082
   Bobo WV, 2011, PSYCHIAT RES, V189, P200, DOI 10.1016/j.psychres.2011.07.008
   Bogenschutz MP, 2004, J CLIN PSYCHIAT, V65, P104
   Bortnick B, 2011, J AFFECT DISORDERS, V128, P83, DOI 10.1016/j.jad.2010.06.031
   Bradburn MJ, 2009, METAANALYSIS STATA U
   Breier A, 2002, BIOL PSYCHIAT, V52, P438, DOI 10.1016/S0006-3223(02)01392-6
   Bruggeman R, 2001, J CLIN PSYCHIAT, V62, P50, DOI 10.4088/JCP.v62n0111
   Buchanan RW, 2005, AM J PSYCHIAT, V162, P124, DOI 10.1176/appi.ajp.162.1.124
   Buckley PF, 2004, SCHIZOPHR RES, V66, P143, DOI 10.1016/j.schres.2003.06.001
   Budman CL, 2001, J CLIN PSYCHIAT, V62, P290, DOI 10.4088/JCP.v62n0412
   Bushe C, 2010, J PSYCHOPHARMACOL, V24, P1001, DOI 10.1177/0269881108101783
   Bushe CJ, 2013, J PSYCHOPHARMACOLOGY
   Butterfield MI, 2001, INT CLIN PSYCHOPHARM, V16, P197, DOI 10.1097/00004850-200107000-00003
   Calabrese JR, 2005, AM J PSYCHIAT, V162, P1351, DOI 10.1176/appi.ajp.162.7.1351
   Canuso CM, 2008, INT CLIN PSYCHOPHARM, V23, P209, DOI 10.1097/YIC.0b013e3282fce651
   Canuso CM, 2010, INT CLIN PSYCHOPHARM, V25, P155, DOI 10.1097/YIC.0b013e3283372977
   Casey Daniel E, 2005, Am J Med, V118 Suppl 2, p15S
   Chan HY, 2007, J CLIN PSYCHIAT, V68, P29, DOI 10.4088/JCP.v68n0104
   Chawla B, 2008, HUM PSYCHOPHARM CLIN, V23, P211, DOI 10.1002/hup.921
   Chen CH, 2011, PROG NEURO-PSYCHOPH, V35, P965, DOI 10.1016/j.pnpbp.2011.01.015
   Chengappa KNR, 2003, CAN J PSYCHIAT, V48, P187
   Chiu CC, 2006, J CLIN PSYCHOPHARM, V26, P504, DOI 10.1097/01.jcp.0000237947.80764.d9
   Chiu CC, 2010, PROG NEURO-PSYCHOPH, V34, P866, DOI 10.1016/j.pnpbp.2010.04.003
   Chiu NY, 2003, PSYCHIAT CLIN NEUROS, V57, P478, DOI 10.1046/j.1440-1819.2003.01151.x
   Christensen AF, 2006, ACTA PSYCHIAT SCAND, V113, P148, DOI 10.1111/j.1600-0447.2005.00736.x
   Chrzanowski WK, 2006, PSYCHOPHARMACOLOGY, V189, P259, DOI 10.1007/s00213-006-0564-3
   Chue P, 2005, EUR NEUROPSYCHOPHARM, V15, P111, DOI 10.1016/j.euroneuro.2004.07.003
   Chue P, 2005, J APPL RES, V5, P246
   Citrome L, 2005, SOUTH MED J, V98, P714, DOI 10.1097/01.smj.0000167621.49292.11
   Ciudad A, 2006, PROG NEURO-PSYCHOPH, V30, P1515, DOI 10.1016/j.pnpbp.2006.05.010
   Cohen SA, 2004, J CLIN PSYCHIAT, V65, P110
   Conley RR, 2005, CLIN NEUROPHARMACOL, V28, P163, DOI 10.1097/01.wnf.0000172993.89879.0f
   Conley RR, 2001, AM J PSYCHIAT, V158, P765, DOI 10.1176/appi.ajp.158.5.765
   Covell NH, 2004, SCHIZOPHRENIA BULL, V30, P229, DOI 10.1093/oxfordjournals.schbul.a007074
   Czobor P, 2002, J CLIN PSYCHOPHARM, V22, P244, DOI 10.1097/00004714-200206000-00003
   Daly EJ, 2013, ANN CLIN PSYCHIATRY, V25, P173
   Daumit GL, 2013, NEW ENGL J MED, V369, P486, DOI 10.1056/NEJMc1306994
   Davidson M, 2007, SCHIZOPHR RES, V93, P117, DOI 10.1016/j.schres.2007.03.003
   De Deyn P, 2005, J CLIN PSYCHOPHARM, V25, P463, DOI 10.1097/01.jcp.0000178415.22309.8f
   De Deyn PP, 2004, INT J GERIATR PSYCH, V19, P115, DOI 10.1002/gps.1032
   de Haan L, 2004, PSYCHOPHARMACOLOGY, V175, P389, DOI 10.1007/s00213-004-1951-2
   De Hert M, 2006, Clin Pract Epidemiol Ment Health, V2, P14
   De Hert M, 2008, SCHIZOPHR RES, V101, P295, DOI 10.1016/j.schres.2008.01.028
   Hert M, 2012, NAT REV ENDOCRINOL, V8, P114, DOI 10.1038/nrendo.2011.156
   de Lima MS, 2005, J CLIN PSYCHIAT, V66, P831, DOI 10.4088/JCP.v66n0704
   Deberdt WG, 2005, AM J GERIAT PSYCHIAT, V13, P722, DOI 10.1176/appi.ajgp.13.8.722
   Dickerson FB, 2006, ACTA PSYCHIAT SCAND, V113, P306, DOI 10.1111/j.1600-0447.2005.00637.x
   Dossenbach M, 2007, J CLIN PSYCHOPHARM, V27, P329, DOI 10.1097/JCP.0b013e3180ca83b1
   Dossenbach MRK, 2001, J CLIN PSYCHIAT, V62, P28
   Drukker M, 2010, SOC PSYCH PSYCH EPID, V45, P475, DOI 10.1007/s00127-009-0088-3
   Emsley R, 2004, J CLIN PSYCHIAT, V65, P696
   Emsley R, 2008, INT CLIN PSYCHOPHARM, V23, P343, DOI 10.1097/YIC.0b013e328314e1f3
   Emsley R, 2008, J CLIN PSYCHOPHARM, V28, P210, DOI 10.1097/JCP.0b013e318167269d
   Enger C, 2004, J NERV MENT DIS, V192, P19, DOI 10.1097/01.nmd.0000105996.62105.07
   Faries DE, 2008, CURR MED RES OPIN, V24, P1399, DOI [10.1185/030079908X297385, 10.1185/030079908X297385 ]
   Fleischhacker WW, 2008, J CLIN PSYCHIAT, V69, P514, DOI 10.4088/JCP.v69n0401
   Fleischhacker WW, 2009, BIOL PSYCHIAT, V65, P510, DOI 10.1016/j.biopsych.2008.07.033
   Forsthoff A, 2007, WORLD J BIOL PSYCHIA, V8, P256, DOI 10.1080/15622970601169766
   Gaebel W, 2010, NEUROPSYCHOPHARMACOL, V35, P2367, DOI 10.1038/npp.2010.111
   Gasquet I, 2005, INT CLIN PSYCHOPHARM, V20, P199, DOI 10.1097/00004850-200507000-00002
   Gastpar M, 2005, J PSYCHOPHARMACOL, V19, P32, DOI 10.1177/0269881105056598
   Gentile S, 2009, OBES REV, V10, P527, DOI 10.1111/j.1467-789X.2009.00589.x
   Gharabawi Georges M, 2007, Ann Gen Psychiatry, V6, P3, DOI 10.1186/1744-859X-6-3
   Godleski LS, 2003, J CLIN PSYCHIAT, V64, P119, DOI 10.4088/JCP.v64n0203
   Gomez-Esteban JC, 2005, CLIN NEUROPHARMACOL, V28, P111
   Gonzalez ALM, 2005, J CLIN PSYCHOPHARM, V25, P533, DOI 10.1097/01.jcp.0000186872.04984.56
   Gopal S, 2011, J PSYCHOPHARMACOL, V25, P685, DOI 10.1177/0269881110372817
   Gothelf D, 2002, AM J PSYCHIAT, V159, P1055, DOI 10.1176/appi.ajp.159.6.1055
   Graham KA, 2008, SCHIZOPHR RES, V101, P287, DOI 10.1016/j.schres.2007.12.476
   Guille C, 2000, J CLIN PSYCHIAT, V61, P638, DOI 10.4088/JCP.v61n0907
   Guo XF, 2011, PSYCHOPHARMACOLOGY, V216, P475, DOI 10.1007/s00213-011-2242-3
   Gupta S, 2004, SCHIZOPHR RES, V70, P57, DOI 10.1016/j.schres.2003.09.016
   Hassler F, 2008, PHARMACOPSYCHIATRY, V41, P232, DOI 10.1055/s-0028-1082072
   Han C, 2007, PROG NEURO-PSYCHOPH, V31, P1219, DOI 10.1016/j.pnpbp.2007.04.017
   Hardy TA, 2011, DIABETES OBES METAB, V13, P726, DOI 10.1111/j.1463-1326.2011.01398.x
   Haro JM, 2007, EUR NEUROPSYCHOPHARM, V17, P235, DOI 10.1016/j.euroneuro.2006.09.005
   Hasnain M, 2013, POSTGRAD MED, V125, P117, DOI 10.3810/pgm.2013.09.2706
   Hatta K, 2009, SCHIZOPHR RES, V113, P49, DOI 10.1016/j.schres.2009.05.030
   Henderson DC, 2008, J CLIN PSYCHIAT, V69, P32
   Henderson DC, 2000, AM J PSYCHIAT, V157, P975, DOI 10.1176/appi.ajp.157.6.975
   Hennen J, 2004, J CLIN PSYCHIAT, V65, P1679, DOI 10.4088/JCP.v65n1214
   Herran A, 2001, BRIT J PSYCHIAT, V179, P59, DOI 10.1192/bjp.179.1.59
   Herrera-Estrella M, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-22
   Hill AL, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-28
   Hirsch SR, 2002, J CLIN PSYCHIAT, V63, P516, DOI 10.4088/JCP.v63n0609
   Hollifield M, 2005, DEPRESS ANXIETY, V21, P33, DOI 10.1002/da.20050
   Holt RIG, 2009, DIABETES OBES METAB, V11, P665, DOI 10.1111/j.1463-1326.2009.01038.x
   Hori H, 2009, WORLD J BIOL PSYCHIA, V10, P741, DOI [10.1080/15622970903166312, 10.3109/15622970903166312]
   Hosojima H, 2006, J PSYCHOPHARMACOL, V20, P75, DOI 10.1177/0269881105056647
   Hsieh MH, 2010, ANN GEN PSYCHIATR, V9, DOI 10.1186/1744-859X-9-35
   Huxley R, 2010, EUR J CLIN NUTR, V64, P16, DOI 10.1038/ejcn.2009.68
   Hwang JP, 2003, J CLIN PSYCHOPHARM, V23, P113, DOI 10.1097/00004714-200304000-00002
   Hwang TJ, 2003, J FORMOS MED ASSOC, V102, P30
   Ingole Shahu, 2009, Indian J Physiol Pharmacol, V53, P47
   Jeste DV, 2003, AM J GERIAT PSYCHIAT, V11, P638, DOI 10.1176/appi.ajgp.11.6.638
   Johnsen E, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-31
   Jones B, 2001, J CLIN PSYCHIAT, V62, P41
   Kane J, 2007, SCHIZOPHR RES, V90, P147, DOI 10.1016/j.schres.2006.09.012
   Kane JM, 2006, INT CLIN PSYCHOPHARM, V21, P21, DOI 10.1097/01.yic.0000182114.65134.81
   Kane JM, 2002, J CLIN PSYCHIAT, V63, P763, DOI 10.4088/JCP.v63n0903
   Kane JM, 2008, J CLIN PSYCHOPHARM, V28, pS29, DOI 10.1097/JCP0b013e318169cca7
   Kane JM, 2011, J CLIN PSYCHIAT, V72, P349, DOI 10.4088/JCP.10m06306
   Kane JM, 2011, J CLIN PSYCHIAT, V72, P194, DOI 10.4088/JCP.07m03733yel
   Kane JM, 2010, AM J PSYCHIAT, V167, P181, DOI 10.1176/appi.ajp.2009.07081221
   Kane JM, 2009, J CLIN PSYCHIAT, V70, P572, DOI 10.4088/JCP.08m04421
   Karagianis J, 2009, SCHIZOPHR RES, V113, P41, DOI 10.1016/j.schres.2009.05.024
   Karagianis J, 2009, CURR MED RES OPIN, V25, P2121, DOI 10.1185/03007990903102966
   Karayal ON, 2011, J PSYCHIATR PRACT, V17, P100, DOI 10.1097/01.pra.0000396061.05269.c8
   Kasper S, 2003, INT J NEUROPSYCHOPH, V6, P325, DOI 10.1017/S1461145703003651
   Keck PE, 2009, J AFFECT DISORDERS, V112, P36, DOI 10.1016/j.jad.2008.05.014
   Keck PE, 2007, J CLIN PSYCHIAT, V68, P1480, DOI 10.4088/JCP.v68n1003
   Keck PE, 2003, AM J PSYCHIAT, V160, P1651, DOI 10.1176/appi.ajp.160.9.1651
   Keefe RSE, 2006, BIOL PSYCHIAT, V59, P97, DOI 10.1016/j.biopsych.2005.06.022
   Keks NA, 2007, BRIT J PSYCHIAT, V191, P131, DOI 10.1192/bjp.bp.105.017020
   Kelly Deanna L, 2003, Ann Clin Psychiatry, V15, P181, DOI 10.3109/10401230309085687
   Kelly DL, 2008, ANN CLIN PSYCHIATRY, V20, P71, DOI 10.1080/10401230802017050
   Kemp DE, 2010, J CLIN PSYCHIAT, V71, P1138, DOI 10.4088/JCP.09m05159gre
   Kerwin R, 2007, EUR PSYCHIAT, V22, P433, DOI 10.1016/j.eurpsy.2007.03.002
   Kim DH, 2009, NEUROTHERAPEUTICS, V6, P78, DOI 10.1016/j.nurt.2008.10.020
   Kim SW, 2007, PROG NEURO-PSYCHOPH, V31, P1504, DOI 10.1016/j.pnpbp.2007.07.005
   Kim SW, 2010, CLIN NEUROPHARMACOL, V33, P121, DOI 10.1097/WNF.0b013e3181d52b85
   Kim SW, 2009, HUM PSYCHOPHARM CLIN, V24, P565, DOI 10.1002/hup.1057
   Kingsbury SJ, 2001, J CLIN PSYCHIAT, V62, P347, DOI 10.4088/JCP.v62n0507
   Kinon BJ, 2000, J CLIN PSYCHIAT, V61, P833, DOI 10.4088/JCP.v61n1105
   Kinon BJ, 2006, J CLIN PSYCHOPHARM, V26, P157, DOI 10.1097/01.jcp.0000204137.82298.06
   Kinon BJ, 2005, J CLIN PSYCHOPHARM, V25, P255, DOI 10.1097/01.jcp.0000161501.65890.22
   Kinon BJ, 2001, J CLIN PSYCHIAT, V62, P92, DOI 10.4088/JCP.v62n0204
   Kinon BJ, 2004, PROG NEURO-PSYCHOPH, V28, P985, DOI 10.1016/j.pnpbp.2004.05.016
   Kinon BJ, 2003, INT J NEUROPSYCHOPH, V6, P97, DOI 10.1017/51461145703003389
   Kinon BJ, 2008, J CLIN PSYCHOPHARM, V28, P601, DOI 10.1097/JCP.0b013e31818aaf6c
   Kinon BJ, 2008, J CLIN PSYCHOPHARM, V28, P392, DOI 10.1097/JCP.0b013e31817e63a5
   Klemp M, 2011, J CLIN PSYCHOPHARM, V31, P698, DOI 10.1097/JCP.0b013e31823657d9
   Kluge M, 2009, PSYCHONEUROENDOCRINO, V34, P118, DOI 10.1016/j.psyneuen.2008.08.016
   Krakowski M, 2009, SCHIZOPHR RES, V110, P95, DOI 10.1016/j.schres.2009.02.006
   Kramer M, 2007, J CLIN PSYCHOPHARM, V27, P6, DOI 10.1097/JCP.0b013e31802dda4a
   Lahti M, 2012, PSYCHOL MED, V42, P2275, DOI 10.1017/S0033291712000396
   Lal S, 2006, J PSYCHIATR NEUROSCI, V31, P271
   Lambert M, 2005, ACTA PSYCHIAT SCAND, V111, P232, DOI 10.1111/j.1600-0447.2004.00451.x
   Lane HY, 2004, PSYCHOPHARMACOLOGY, V172, P393, DOI 10.1007/s00213-003-1685-6
   Lane HY, 2003, J CLIN PSYCHIAT, V64, P316, DOI 10.4088/JCP.v64n0314
   Lasser R, 2004, J AFFECT DISORDERS, V83, P263, DOI 10.1016/j.jad.2004.05.008
   Lasser RA, 2004, EUR PSYCHIAT, V19, P219, DOI 10.1016/j.eurpsy.2003.11.007
   Lauriello J, 2008, J CLIN PSYCHIAT, V69, P790, DOI 10.4088/JCP.v69n0512
   Lecrubier Y, 2006, ACTA PSYCHIAT SCAND, V114, P319, DOI 10.1111/j.1600-0447.2006.00887.x
   Lee C, 2006, AUST NZ J PSYCHIAT, V40, P437, DOI 10.1111/j.1440-1614.2006.01820.x
   Lee CT, 2002, J CLIN PSYCHIAT, V63, P569, DOI 10.4088/JCP.v63n0706
   Lee JS, 2011, CLIN NEUROPHARMACOL, V34, P186, DOI 10.1097/WNF.0b013e3182281c05
   Lee KU, 2009, HUM PSYCHOPHARM CLIN, V24, P447, DOI 10.1002/hup.1047
   Leelahanaj Thawatchai, 2005, J Med Assoc Thai, V88 Suppl 3, pS43
   Leucht S, 2009, PSYCHOL MED, V39, P1591, DOI 10.1017/S0033291709005455
   Leucht S, 2013, LANCET, V382, P951, DOI 10.1016/S0140-6736(13)60733-3
   Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688
   Lindenmayer JP, 2007, J CLIN PSYCHIAT, V68, P368, DOI 10.4088/JCP.v68n0303
   Lindenmayer JP, 2007, EUR NEUROPSYCHOPHARM, V17, P138, DOI 10.1016/j.euroneuro.2006.08.004
   Lindenmayer JP, 2011, J CLIN PSYCHOPHARM, V31, P160, DOI 10.1097/JCP.0b013e31820f4fe0
   Lindenmayer JP, 2001, J CLIN PSYCHOPHARM, V21, P448, DOI 10.1097/00004714-200108000-00014
   Lindenmayer JP, 2004, J CLIN PSYCHIAT, V65, P1084
   Lindenmayer JP, 2002, J CLIN PSYCHIAT, V63, P931, DOI 10.4088/JCP.v63n1011
   Lipkovich I, 2006, J CLIN PSYCHOPHARM, V26, P316, DOI 10.1097/01.jcp.0000219916.88810.1c
   Llorca PM, 2002, J PSYCHIATR NEUROSCI, V27, P30
   Loebel AD, 2007, J CLIN PSYCHIAT, V68, P1333, DOI 10.4088/JCP.v68n0902
   Loebl T, 2008, J CLIN PSYCHIAT, V69, P480, DOI 10.4088/JCP.v69n0321
   Louza MR, 2011, NEUROPSYCH DIS TREAT, V7, P391, DOI 10.2147/NDT.S20589
   Malempati RN, 2008, INT CLIN PSYCHOPHARM, V23, P88, DOI 10.1097/YIC.0b013e3282f2b4c5
   Marder SR, 2003, SCHIZOPHR RES, V61, P123, DOI 10.1016/S0920-9964(03)00050-1
   Marder SR, 2007, BIOL PSYCHIAT, V62, P1363, DOI 10.1016/j.biopsych.2007.01.017
   Margolese HC, 2002, J CLIN PSYCHOPHARM, V22, P347, DOI 10.1097/01.jcp.0000024578.36017.2b
   Haro JM, 2008, J PSYCHIATR RES, V43, P265, DOI 10.1016/j.jpsychires.2008.06.001
   Martin S, 2002, CURR MED RES OPIN, V18, P355, DOI 10.1185/030079902125001128
   Mauri MC, 2007, PHARMACOPSYCHIATRY, V40, P89, DOI 10.1055/s-2007-973835
   Mauri MC, 2005, EUR PSYCHIAT, V20, P55, DOI 10.1016/j.eurpsy.2004.09.009
   McDonnell DP, 2011, HUM PSYCHOPHARMACOL
   McElroy SL, 2008, J CLIN PSYCHIAT, V69, P433, DOI 10.4088/JCP.v69n0314
   McElroy SL, 2009, J CLIN PSYCHIAT, V70, P12, DOI 10.4088/JCP.7075su1c.03
   McEvoy JP, 2007, J PSYCHIATR RES, V41, P895, DOI 10.1016/j.jpsychires.2007.05.002
   McEvoy JP, 2007, AM J PSYCHIAT, V164, P1050, DOI 10.1176/appi.ajp.164.7.1050
   McEvoy JP, 2006, AM J PSYCHIAT, V163, P600, DOI 10.1176/appi.ajp.163.4.600
   McGlashan TH, 2006, AM J PSYCHIAT, V163, P790, DOI 10.1176/appi.ajp.163.5.790
   McIntyre RS, 2003, CAN J PSYCHIAT, V48, P689, DOI 10.1177/070674370304801008
   McIntyre Roger S, 2004, Can J Clin Pharmacol, V11, pe218
   McIntyre RS, 2010, J AFFECT DISORDERS, V126, P358, DOI 10.1016/j.jad.2010.04.005
   McIntyre RS, 2010, J AFFECT DISORDERS, V122, P27, DOI 10.1016/j.jad.2009.12.028
   McIntyre RS, 2009, BIPOLAR DISORD, V11, P673, DOI 10.1111/j.1399-5618.2009.00748.x
   McIntyre RS, 2003, J CLIN PSYCHOPHARM, V23, P323, DOI 10.1097/01.jcp.0000085403.08426.f4
   McIntyre RS, 2001, CAN J PSYCHIAT, V46, P273, DOI 10.1177/070674370104600308
   McQuade RD, 2004, J CLIN PSYCHIAT, V65, P47
   Meltzer HY, 2008, J CLIN PSYCHIAT, V69, P817, DOI 10.4088/JCP.v69n0515
   Meltzer HY, 2008, J CLIN PSYCHIAT, V69, P274, DOI 10.4088/JCP.v69n0214
   Meltzer HY, 2010, PSYCHIAT RES, V177, P286, DOI 10.1016/j.psychres.2010.02.018
   Meltzer HY, 2001, J CLIN PSYCHIAT, V62, P35
   Meltzer HY, 2001, J CLIN PSYCHIAT S27, V62, P40
   Meyer JM, 2009, J CLIN PSYCHIAT, V70, P318, DOI 10.4088/JCP.08m04267
   Mitchell AJ, 2013, SCHIZOPHRENIA BULL, V39, P306, DOI 10.1093/schbul/sbr148
   Moeller H-J, 2008, J CLIN PSYCHOPHARM, V23, P95
   Mohl A, 2005, J PSYCHOPHARMACOL, V19, P22, DOI 10.1177/0269881105056515
   Moller HJ, 2005, INT CLIN PSYCHOPHARM, V20, P121
   Moretti Rita, 2004, Am J Alzheimers Dis Other Demen, V19, P81, DOI 10.1177/153331750401900215
   Murashita M, 2005, PSYCHONEUROENDOCRINO, V30, P106, DOI 10.1016/j.psyneuen.2004.05.008
   Muzina DJ, 2008, INT J CLIN PRACT, V62, P679, DOI 10.1111/j.1742-1241.2008.01735.x
   Naber D, 2005, ACTA PSYCHIAT SCAND, V111, P106, DOI 10.1111/j.1600-0447.2004.00486.x
   Nakamura M, 2009, J CLIN PSYCHIAT, V70, P829, DOI 10.4088/JCP.08m04905
   Neovius M, 2007, ACTA PSYCHIAT SCAND, V115, P277, DOI 10.1111/j.1600-0447.2006.00899.x
   Newcomer JW, 2008, J CLIN PSYCHIAT, V69, P1046, DOI 10.4088/JCP.v69n0702
   Newcomer JW, 2007, J CLIN PSYCHIAT, V68, P8
   Newcomer JW, 2006, CAN J PSYCHIAT, V51, P480, DOI 10.1177/070674370605100803
   Newcomer JW, 2013, J CLIN PSYCHIAT, V74, P1108, DOI 10.4088/JCP.12028ah1
   Newcomer JW, 2009, J CLIN PSYCHIAT, V70, P30, DOI 10.4088/JCP.7075su1c.05
   Newcomer JW, 2009, J CLIN PSYCHIAT, V70, P487, DOI 10.4088/JCP.08m04132
   Newcomer JW, 2004, CLIN THER, V26, P1936, DOI 10.1016/j.clinthera.2004.12.003
   Nick B, 2006, INT J PSYCHIAT CLIN, V10, P174, DOI 10.1080/13651500600633477
   Olie JP, 2006, INT CLIN PSYCHOPHARM, V21, P143
   Osby U, 2001, ARCH GEN PSYCHIAT, V58, P844, DOI 10.1001/archpsyc.58.9.844
   Osser DN, 1999, J CLIN PSYCHIAT, V60, P767, DOI 10.4088/JCP.v60n1109
   Ozguven HD, 2011, METABOLIC EFFECTS OL, V4, P10
   Pae CU, 2009, EUR NEUROPSYCHOPHARM, V19, P562, DOI 10.1016/j.euroneuro.2009.04.002
   Panariello F, 2011, SCHIZOPHR RES TREAT, DOI 10.1155/2011/459284
   Pandina G, 2011, PROG NEURO-PSYCHOPH, V35, P218, DOI 10.1016/j.pnpbp.2010.11.008
   Parellada E, 2010, INT CLIN PSYCHOPHARM, V25, P149, DOI 10.1097/YIC.0b013e328336c93f
   Parsons B, 2009, SCHIZOPHR RES, V110, P103, DOI 10.1016/j.schres.2008.09.025
   Perez-Iglesias R, 2007, J CLIN PSYCHIAT, V68, P1733, DOI 10.4088/JCP.v68n1113
   Perlis RH, 2006, J CLIN PSYCHIAT, V67, P1747, DOI 10.4088/JCP.v67n1112
   Perry PJ, 2005, J CLIN PSYCHOPHARM, V25, P250, DOI 10.1097/01.jcp.0000162800.64378.82
   Peuskens J, 1999, PSYCHIAT RES, V88, P107, DOI 10.1016/S0165-1781(99)00075-X
   Peuskens J, 2009, EUR PSYCHIAT, V24, P154, DOI 10.1016/j.eurpsy.2008.11.002
   Peuskens J, 2007, INT CLIN PSYCHOPHARM, V22, P145, DOI 10.1097/YIC.0b013e3280148c29
   Pigott TA, 2003, J CLIN PSYCHIAT, V64, P1048, DOI 10.4088/JCP.v64n0910
   Popovic V, 2007, NEUROENDOCRINOLOGY, V85, P249, DOI 10.1159/000103868
   Potkin SG, 2003, ARCH GEN PSYCHIAT, V60, P681, DOI 10.1001/archpsyc.60.7.681
   Potkin SG, 2007, J CLIN PSYCHIAT, V68, P1492, DOI 10.4088/JCP.v68n1004
   Potkin SG, 2006, SCHIZOPHR RES, V85, P254, DOI 10.1016/j.schres.2006.03.027
   Potkin SG, 2011, SCHIZOPHR RES, V132, P101, DOI 10.1016/j.schres.2011.04.008
   Quiroz JA, 2010, BIOL PSYCHIAT, V68, P156, DOI 10.1016/j.biopsych.2010.01.015
   [R Core Team Computing RFfS], 2013, R LANG ENV STAT COMP
   Reich DB, 2004, J CLIN PSYCHIAT, V65, P1601, DOI 10.4088/JCP.v65n1204
   Revicki DA, 1999, QUAL LIFE RES, V8, P417, DOI 10.1023/A:1008958925848
   Riedel M, 2007, EUR ARCH PSY CLIN N, V257, P402, DOI 10.1007/s00406-007-0748-9
   Ritchie CW, 2003, INT J GERIATR PSYCH, V18, P432, DOI 10.1002/gsp.862
   Rodriguez-Perez V, 2002, PROG NEURO-PSYCHOPH, V26, P1055, DOI 10.1016/S0278-5846(02)00222-1
   Roerig JL, 2008, J CLIN PSYCHOPHARM, V28, P21, DOI 10.1097/jcp.0b013e3181613325
   Rossi A, 2009, HUM PSYCHOPHARM CLIN, V24, P574, DOI 10.1002/hup.1067
   Rothman K, 1998, MODERN EPIDEMIOLOGY
   Ruhrmann S, 2007, PROG NEURO-PSYCHOPH, V31, P1012, DOI 10.1016/j.pnpbp.2007.02.014
   Rummel-Kluge C, 2010, SCHIZOPHR B
   Ryckmans V, 2009, PHARMACOPSYCHIATRY, V42, P114, DOI 10.1055/s-0028-1112134
   Sacchetti E, 2004, SCHIZOPHR RES, V69, P325, DOI 10.1016/S0920-9964(03)00225-1
   Sacchetti E, 2008, SCHIZOPHR RES, V98, P55, DOI 10.1016/j.schres.2007.09.011
   Sacchetti E, 2009, SCHIZOPHR RES, V113, P112, DOI 10.1016/j.schres.2009.05.002
   Sachs G, 2006, J PSYCHOPHARMACOL, V20, P536, DOI 10.1177/0269881106059693
   Saddichha S, 2008, ACTA PSYCHIAT SCAND, V117, P342, DOI 10.1111/j.1600-0447.2008.01158.x
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Sajatovic M, 2001, J CLIN PSYCHIAT, V62, P728, DOI 10.4088/JCP.v62n0911
   Sajatovic M, 2008, BIPOLAR DISORD, V10, P662, DOI 10.1111/j.1399-5618.2008.00614.x
   Sajatovic M, 2008, J CLIN PSYCHIAT, V69, P41, DOI 10.4088/JCP.v69n0106
   Sanger TM, 2001, J CLIN PSYCHIAT, V62, P273, DOI 10.4088/JCP.v62n0410
   Sanger TM, 2003, J AFFECT DISORDERS, V73, P155, DOI 10.1016/S0165-0327(02)00334-8
   Schneider LS, 2006, NEW ENGL J MED, V355, P1525, DOI 10.1056/NEJMoa061240
   Schoemaker J, 2010, PHARMACOPSYCHIATRY, V43, P138, DOI 10.1055/s-0030-1248313
   Schooler N, 2005, AM J PSYCHIAT, V162, P947, DOI 10.1176/appi.ajp.162.5.947
   Schulz SC, 2008, BRIT J PSYCHIAT, V193, P485, DOI 10.1192/bjp.bp.107.037903
   Schulz SC, 1999, BIOL PSYCHIAT, V46, P1429, DOI 10.1016/S0006-3223(99)00128-6
   Sechter D, 2002, NEUROPSYCHOPHARMACOL, V27, P1071, DOI 10.1016/S0893-133X(02)00375-5
   Seidell JC, 2010, EUR J CLIN NUTR, V64, P35, DOI 10.1038/ejcn.2009.71
   Sevy S, 2011, PSYCHIAT RES, V188, P310, DOI 10.1016/j.psychres.2011.05.001
   Sheehan DV, 2009, J AFFECT DISORDERS, V115, P376, DOI 10.1016/j.jad.2008.10.005
   Simpson GM, 2005, AM J PSYCHIAT, V162, P1535, DOI 10.1176/appi.ajp.162.8.1535
   Simpson GM, 2004, AM J PSYCHIAT, V161, P1837, DOI 10.1176/appi.ajp.161.10.1837
   Simpson MM, 2001, J CLIN PSYCHIAT, V62, P694, DOI 10.4088/JCP.v62n0906
   Smith E, 2008, INT CLIN PSYCHOPHARM, V23, P130, DOI 10.1097/YIC.0b013e3282f424d6
   Smith RC, 2009, J CLIN PSYCHIAT, V70, P1501, DOI 10.4088/JCP.08m04446yel
   Smulevich AB, 2005, EUR NEUROPSYCHOPHARM, V15, P75, DOI 10.1016/j.euroneuro.2004.06.003
   Soler J, 2005, AM J PSYCHIAT, V162, P1221, DOI 10.1176/appi.ajp.162.6.1221
   Sowell MO, 2002, J CLIN ENDOCR METAB, V87, P2918, DOI 10.1210/jc.87.6.2918
   Spivak B, 1999, INT CLIN PSYCHOPHARM, V14, P229, DOI 10.1097/00004850-199907000-00004
   Starrenburg FCJ, 2009, EUR PSYCHIAT, V24, P164, DOI 10.1016/j.eurpsy.2009.01.001
   Statacorp, 2012, STAT SOFTW REL 12
   Strassnig M, 2007, SCHIZOPHR RES, V93, P90, DOI 10.1016/j.schres.2007.02.024
   Street JS, 2001, INT J GERIATR PSYCH, V16, pS62, DOI 10.1002/1099-1166(200112)16:1+<::AID-GPS569>3.0.CO;2-J
   Streim JE, 2008, AM J GERIAT PSYCHIAT, V16, P537, DOI 10.1097/JGP.0b013e318165db77
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Stroup TS, 2007, AM J PSYCHIAT, V164, P415, DOI 10.1176/appi.ajp.164.3.415
   Stroup TS, 2011, AM J PSYCHIAT, V168, P947, DOI 10.1176/appi.ajp.2011.10111609
   Stroup TS, 2009, SCHIZOPHR RES, V107, P1, DOI 10.1016/j.schres.2008.10.011
   Stroup TS, 2006, AM J PSYCHIAT, V163, P611, DOI 10.1176/appi.ajp.163.4.611
   Strous RD, 2006, HUM PSYCHOPHARM CLIN, V21, P235, DOI 10.1002/hup.764
   Suppes T, 2010, J AFFECT DISORDERS, V121, P106, DOI 10.1016/j.jad.2009.10.007
   Takahashi H, 2009, CLIN NEUROPHARMACOL, V32, P149, DOI 10.1097/WNF.0b013e31817c6b06
   Tamayo JM, 2007, J CLIN PSYCHOPHARM, V27, P126, DOI 10.1097/JCP.0b013e318033bd4a
   Tariot PN, 2000, CLIN THER, V22, P1068, DOI 10.1016/S0149-2918(00)80085-5
   Tarricone I, 2010, PSYCHOL MED, V40, P187, DOI 10.1017/S0033291709990407
   Tauscher-Wisniewski S, 2002, J CLIN PSYCHIAT, V63, P992, DOI 10.4088/JCP.v63n1106
   Thase ME, 2008, J CLIN PSYCHOPHARM, V28, P13, DOI 10.1097/jcp.0b013e3181618eb4
   Thase ME, 2006, J CLIN PSYCHOPHARM, V26, P600, DOI 10.1097/01.jcp.0000248603.76231.b7
   Theisen FM, 2005, PSYCHIAT GENET, V15, P285, DOI 10.1097/00041444-200512000-00011
   Tiihonen J, 2009, LANCET, V374, P620, DOI 10.1016/S0140-6736(09)60742-X
   Tiihonen K, 2010, BRIT J NUTR, V103, P1070, DOI 10.1017/S0007114509992807
   Tohen M, 2000, ARCH GEN PSYCHIAT, V57, P841, DOI 10.1001/archpsyc.57.9.841
   Tohen M, 2003, ARCH GEN PSYCHIAT, V60, P1218, DOI 10.1001/archpsyc.60.12.1218
   Tohen M, 2006, AM J PSYCHIAT, V163, P247, DOI 10.1176/appi.ajp.163.2.247
   Tollefson GD, 2001, BIOL PSYCHIAT, V49, P52, DOI 10.1016/S0006-3223(00)01026-X
   Tran PV, 1999, BRIT J PSYCHIAT, V174, P15, DOI 10.1192/bjp.174.1.15
   Treuer T, 2009, WORLD J BIOL PSYCHIA, V10, P729, DOI [10.3109/15622970903079507, 10.1080/15622970903079507]
   Van Ameringen M, 2010, J CLIN PSYCHIAT, V71, P1336, DOI 10.4088/JCP.09m05114gre
   van Bruggen J, 2003, INT CLIN PSYCHOPHARM, V18, P341, DOI 10.1097/01.yic.0000097037.25861.df
   van Dooren FEP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057058
   van Winkel R, 2008, BIPOLAR DISORD, V10, P342, DOI 10.1111/j.1399-5618.2007.00520.x
   Vanelle JM, 2006, EUR PSYCHIAT, V21, P523, DOI 10.1016/j.eurpsy.2006.09.003
   Vieta E, 2007, BIPOLAR DISORD, V9, P413, DOI 10.1111/j.1399-5618.2007.00479.x
   Vieta E, 2004, HUM PSYCHOPHARM CLIN, V19, P41, DOI 10.1002/hup.556
   Villarreal G, 2007, PSYCHOPHARMACOL BULL, V40, P6
   Villeneuve E, 2005, J CLIN PSYCHIAT, V66, P1298, DOI 10.4088/JCP.v66n1013
   Wang XH, 2006, J PSYCHIATR RES, V40, P669, DOI 10.1016/j.jpsychires.2006.03.008
   Weiden PJ, 2008, J CLIN PSYCHOPHARM, V28, pS12, DOI [10.1097/JCP.0b013e3181694f5a, 10.1097/JCR.0b013e3181694f5a]
   Weiden PJ, 2003, J CLIN PSYCHIAT, V64, P580, DOI 10.4088/JCP.v64n0514
   Weinmann S, 2009, SCHIZOPHR RES, V113, P1, DOI 10.1016/j.schres.2009.05.018
   Weisler R, 2009, CNS SPECTRUMS, V14, P299, DOI 10.1017/S1092852900020307
   White MP, 2011, J CLIN PSYCHOPHARM, V31, P503, DOI 10.1097/JCP.0b013e318221b1ba
   Wirshing DA, 1999, J CLIN PSYCHIAT, V60, P358, DOI 10.4088/JCP.v60n0602
   Xiang YT, 2011, PHARMACOPSYCHIATRY, V44, P135, DOI 10.1055/s-0031-1277178
   Yang J, 2010, CLIN NEUROPHARMACOL, V33, P169, DOI 10.1097/WNF.0b013e3181dcda50
   Yap H. L., 2001, SMJ Singapore Medical Journal, V42, P170
   Young AH, 2009, BRIT J PSYCHIAT, V194, P40, DOI 10.1192/bjp.bp.108.049965
   Zanarini MC, 2011, J CLIN PSYCHIAT, V72, P1353, DOI 10.4088/JCP.08m04138yel
   Zanarini MC, 2001, J CLIN PSYCHIAT, V62, P849, DOI 10.4088/JCP.v62n1103
   Zhong KX, 2006, J CLIN PSYCHIAT, V67, P1093, DOI 10.4088/JCP.v67n0712
   Zimbroff D, 2007, INT CLIN PSYCHOPHARM, V22, P363, DOI 10.1097/YIC.0b013e32816f7779
   Zipursky RB, 2005, BRIT J PSYCHIAT, V187, P537, DOI 10.1192/bjp.187.6.537
NR 359
TC 143
Z9 148
U1 2
U2 45
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 24
PY 2014
VL 9
IS 4
AR e94112
DI 10.1371/journal.pone.0094112
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG6CB
UT WOS:000335505000006
PM 24763306
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Foley, DL
   Mackinnon, A
   Watts, GF
   Shaw, JE
   Magliano, DJ
   Castle, DJ
   McGrath, JJ
   Waterreus, A
   Morgan, VA
   Galletly, CA
AF Foley, Debra L.
   Mackinnon, Andrew
   Watts, Gerald F.
   Shaw, Jonathan E.
   Magliano, Dianna J.
   Castle, David J.
   McGrath, John J.
   Waterreus, Anna
   Morgan, Vera A.
   Galletly, Cherrie A.
TI Cardiometabolic Risk Indicators That Distinguish Adults with Psychosis
   from the General Population, by Age and Gender
SO PLOS ONE
LA English
DT Article
ID IMPAIRED GLUCOSE-TOLERANCE; AUSTRALIAN NATIONAL-SURVEY; DRUG-NAIVE
   PATIENTS; 1ST-EPISODE SCHIZOPHRENIA; CARDIOVASCULAR RISK;
   INSULIN-RESISTANCE; FASTING GLUCOSE; MENTAL-ILLNESS; METABOLIC RISK;
   MORTALITY
AB Individuals with psychosis are more likely than the general community to develop obesity and to die prematurely from heart disease. Interventions to improve cardiovascular outcomes are best targeted at the earliest indicators of risk, at the age they first emerge. We investigated which cardiometabolic risk indicators distinguished those with psychosis from the general population, by age by gender, and whether obesity explained the pattern of observed differences. Data was analyzed from an epidemiologically representative sample of 1,642 Australians with psychosis aged 18-64 years and a national comparator sample of 8,866 controls aged 25-64 years from the general population. Cubic b-splines were used to compare cross sectional age trends by gender for mean waist circumference, body mass index [BMI], blood pressure, fasting blood glucose, triglycerides, LDL, HDL, and total cholesterol in our psychosis and control samples. At age 25 individuals with psychosis had a significantly higher mean BMI, waist circumference, triglycerides, glucose [women only], and diastolic blood pressure and significantly lower HDL-cholesterol than controls. With the exception of triglycerides at age 60+ in men, and glucose in women at various ages, these differences were present at every age. Differences in BMI and waist circumference between samples, although dramatic, could not explain all differences in diastolic blood pressure, HDL-cholesterol or triglycerides but did explain differences in glucose. Psychosis has the hallmarks of insulin resistance by at least age 25. The entire syndrome, not just weight, should be a focus of intervention to reduce mortality from cardiovascular disease.
C1 [Foley, Debra L.; Mackinnon, Andrew] Univ Melbourne, Orygen Youth Hlth Res Ctr, Melbourne, Vic 3010, Australia.
   [Foley, Debra L.; Mackinnon, Andrew] Univ Melbourne, Ctr Youth Mental Hlth, Melbourne, Vic 3010, Australia.
   [Watts, Gerald F.] Univ Western Australia, Lipid Disorders Clin, Metab Res Ctr, Nedlands, WA 6009, Australia.
   [Watts, Gerald F.] Univ Western Australia, Dept Internal Med, Royal Perth Hosp, Nedlands, WA 6009, Australia.
   [Watts, Gerald F.] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6009, Australia.
   [Shaw, Jonathan E.; Magliano, Dianna J.] Baker IDI Heart & Diabet Inst, Dept Clin Diabet & Epidemiol, Melbourne, Vic, Australia.
   [Castle, David J.] St Vincents Hosp, Melbourne, Vic, Australia.
   [Castle, David J.] Univ Melbourne, Dept Psychiat, Melbourne, Vic 3010, Australia.
   [McGrath, John J.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia.
   [Waterreus, Anna; Morgan, Vera A.] Univ Western Australia, Sch Psychiat & Clin Neurosci, Nedlands, WA 6009, Australia.
   [Galletly, Cherrie A.] Univ Adelaide, Discipline Psychiat, Sch Med, Adelaide, SA 5005, Australia.
   [Galletly, Cherrie A.] Northern Adelaide Local Hlth Network, Adelaide, SA, Australia.
RP Foley, DL (reprint author), Univ Melbourne, Orygen Youth Hlth Res Ctr, Melbourne, Vic 3010, Australia.
EM foley.debra@gmail.com
RI McGrath, John J/G-5493-2010; Shaw, Jonathan/E-7388-2010
OI McGrath, John J/0000-0002-4792-6068; Shaw, Jonathan/0000-0002-6187-2203;
   Waterreus, Anna/0000-0002-1648-7701; Mackinnon,
   Andrew/0000-0003-0831-9801
FU Australian Government Department of Health and Ageing; Commonwealth Dept
   of Health and Aged Care; Abbott Australasia Pty Ltd; Alphapharm Pty Ltd;
   AstraZeneca; Aventis Pharmaceutical; Bristol-Myers Squibb
   Pharmaceuticals; Eli Lilly [Aust] Pty Ltd; GlaxoSmithKline;
   Janssen-Cilag [Aust] Pty Ltd; Merck Lipha s.a.; Merck Sharp Dohme
   [Aust]; Novartis Pharmaceutical [Aust] Pty Ltd.; Novo Nordisk
   Pharmaceutical Pty Ltd; Pharmacia and Upjohn Pty Ltd; Pfizer Pty Ltd;
   Roche Diagnostics; Sanofi Synthelabo [Aust] Pty Ltd.; Servier
   Laboratories [Aust] Pty Ltd; BioRad Laboratories Pty Ltd; HITECH
   Pathology Pty Ltd; Australian Kidney Foundation; Diabetes Australia;
   Diabetes Australia [Northern Territory]; Queensland Health; South
   Australian Department of Human Services; Tasmanian Department of Health
   and Human Services; Territory Health Services; Victorian Department of
   Human Services; Victorian OIS program; Health Department of Western
   Australia; Colonial Foundation [Australia]
FX The psychosis survey [the SHIP study] was funded by the Australian
   Government Department of Health and Ageing under contract to The
   University of Western Australia. The general population survey [the
   AusDiab study] was funded by The Commonwealth Dept of Health and Aged
   Care, Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, AstraZeneca,
   Aventis Pharmaceutical, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly
   [Aust] Pty Ltd, GlaxoSmithKline, Janssen-Cilag [Aust] Pty Ltd, Merck
   Lipha s.a., Merck Sharp & Dohme [Aust], Novartis Pharmaceutical [Aust]
   Pty Ltd., Novo Nordisk Pharmaceutical Pty Ltd, Pharmacia and Upjohn Pty
   Ltd, Pfizer Pty Ltd, Roche Diagnostics, Sanofi Synthelabo [Aust] Pty
   Ltd., Servier Laboratories [Aust] Pty Ltd, BioRad Laboratories Pty Ltd,
   HITECH Pathology Pty Ltd, the Australian Kidney Foundation, Diabetes
   Australia, Diabetes Australia [Northern Territory], Queensland Health,
   South Australian Department of Human Services, Tasmanian Department of
   Health and Human Services, Territory Health Services, Victorian
   Department of Human Services, the Victorian OIS program and Health
   Department of Western Australia. Drs Foley and Mackinnon were supported
   by the Colonial Foundation [Australia]. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Albaugh VL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022662
   [Anonymous], AUSDIAB REP 2000
   Bushe CJ, 2010, J PSYCHOPHARMACOL, V24, P17, DOI 10.1177/1359786810382468
   Castle DJ, 2006, PSYCHOL MED, V36, P69, DOI 10.1017/S0033291705005969
   Cohen D, 2011, NEUROPSYCHOPHARMACOL, V36, P2368, DOI 10.1038/npp.2011.94
   Daumit GL, 2013, NEW ENGL J MED, V368, P1594, DOI 10.1056/NEJMoa1214530
   De Hert M, 2011, BRIT J PSYCHIAT, V199, P99, DOI 10.1192/bjp.bp.110.084665
   Hert M, 2012, NAT REV ENDOCRINOL, V8, P114, DOI 10.1038/nrendo.2011.156
   DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173
   DeFronzo RA, 2011, AM J CARDIOL, V108, p3B, DOI 10.1016/j.amjcard.2011.03.013
   Dunstan DW, 2002, DIABETES RES CLIN PR, V57, P119, DOI 10.1016/S0168-8227(02)00025-6
   Foley DL, 2011, ARCH GEN PSYCHIAT, V68, P609, DOI 10.1001/archgenpsychiatry.2011.2
   Galletly CA, 2012, AUST NZ J PSYCHIAT, V46, P753, DOI 10.1177/0004867412453089
   HOLM S, 1979, SCAND J STAT, V6, P65
   Johnson AMF, 2013, CELL, V152, P673, DOI 10.1016/j.cell.2013.01.041
   Kahn RS, 2008, LANCET, V371, P1085, DOI 10.1016/S0140-6736(08)60486-9
   Laursen TM, 2012, CURR OPIN PSYCHIATR, V25, P83, DOI 10.1097/YCO.0b013e32835035ca
   Mitchell AJ, 2012, PSYCHOL MED, V42, P125, DOI 10.1017/S003329171100105X
   Morgan VA, 2012, AUST NZ J PSYCHIAT, V46, P735, DOI 10.1177/0004867412449877
   Morrish NJ, 2001, DIABETOLOGIA, V44, pS14, DOI 10.1007/PL00002934
   Moser DJ, 2002, AM J PSYCHIAT, V159, P1201, DOI 10.1176/appi.ajp.159.7.1201
   Newcomer JW, 2007, J CLIN PSYCHIAT, V68, P8
   Newson R., 2000, STATA TECHNICAL B, V57, P20
   Nielsen J, 2010, NEUROPSYCHOPHARMACOL, V35, P1997, DOI 10.1038/npp.2010.78
   Polymeropoulos MH, 2009, SCHIZOPHR RES, V108, P134, DOI 10.1016/j.schres.2008.11.025
   Remington G, 1998, BRIT J PSYCHIAT, V172, P66, DOI 10.1192/S0007125000297687
   Remington G, 2011, J CLIN PSYCHIAT, V72, P1042, DOI 10.4088/JCP.09m05866yel
   Remington G, 2010, SCHIZOPHRENIA BULL, V36, P900, DOI 10.1093/schbul/sbq083
   Roberts LW, 2000, AM J PSYCHIAT, V157, P67, DOI 10.1176/ajp.157.1.67
   Rouillon F, 2005, EUR PSYCHIAT, V20, pS345, DOI 10.1016/S0924-9338(05)80189-0
   Ryan MCM, 2003, AM J PSYCHIAT, V160, P284, DOI 10.1176/appi.ajp.160.2.284
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Spelman LM, 2007, DIABETIC MED, V24, P481, DOI 10.1111/j.1464-5491.2007.02092.x
   Stroup TS, 2011, AM J PSYCHIAT, V168, P947, DOI 10.1176/appi.ajp.2011.10111609
   Tauscher J, 2001, CNS DRUGS, V15, P671, DOI 10.2165/00023210-200115090-00001
   Thornicroft G, 2011, BRIT J PSYCHIAT, V199, P441, DOI 10.1192/bjp.bp.111.092718
   World Health Organization, 2008, ICD 10 INT STAT CLAS
   Yusuf S, 2005, LANCET, V366, P1640, DOI 10.1016/S0140-6736(05)67663-5
NR 38
TC 28
Z9 28
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 18
PY 2013
VL 8
IS 12
AR e82606
DI 10.1371/journal.pone.0082606
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276HL
UT WOS:000328740300044
PM 24367528
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Baxter, AJ
   Patton, G
   Scott, KM
   Degenhardt, L
   Whiteford, HA
AF Baxter, Amanda J.
   Patton, George
   Scott, Kate M.
   Degenhardt, Louisa
   Whiteford, Harvey A.
TI Global Epidemiology of Mental Disorders: What Are We Missing?
SO PLOS ONE
LA English
DT Article
ID MAJOR DEPRESSION; GENERAL-POPULATION; ANXIETY DISORDERS; SCREENING
   INSTRUMENTS; CATCHMENT-AREA; HEALTH SURVEY; PREVALENCE; MORTALITY;
   SCHIZOPHRENIA; METAANALYSIS
AB Background: Population-based studies provide the understanding of health-need required for effective public health policy and service-planning. Mental disorders are an important but, until recently, neglected agenda in global health. This paper reviews the coverage and limitations in global epidemiological data for mental disorders and suggests strategies to strengthen the data.
   Methods: Systematic reviews were conducted for population-based epidemiological studies in mental disorders to inform new estimates for the global burden of disease study. Estimates of population coverage were calculated, adjusted for study parameters (age, gender and sampling frames) to quantify regional coverage.
   Results: Of the 77,000 data sources identified, fewer than 1% could be used for deriving national estimates of prevalence, incidence, remission, and mortality in mental disorders. The two major limitations were (1) highly variable regional coverage, and (2) important methodological issues that prevented synthesis across studies, including the use of varying case definitions, the selection of samples not allowing generalization, lack of standardized indicators, and incomplete reporting. North America and Australasia had the most complete prevalence data for mental disorders while coverage was highly variable across Europe, Latin America, and Asia Pacific, and poor in other regions of Asia and Africa. Nationally-representative data for incidence, remission, and mortality were sparse across most of the world.
   Discussion: Recent calls to action for global mental health were predicated on the high prevalence and disability of mental disorders. However, the global picture of disorders is inadequate for planning. Global data coverage is not commensurate with other important health problems, and for most of the world's population, mental disorders are invisible and remain a low priority.
C1 [Baxter, Amanda J.; Whiteford, Harvey A.] Univ Queensland, Sch Populat Hlth, Herston, Qld, Australia.
   [Baxter, Amanda J.; Whiteford, Harvey A.] Queensland Ctr Mental Hlth Res, Wacol, Australia.
   [Patton, George] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
   [Patton, George] Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Scott, Kate M.] Univ Otago, Dept Psychol Med, Dunedin, New Zealand.
   [Degenhardt, Louisa] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia.
   [Degenhardt, Louisa] Univ Melbourne, Sch Populat Hlth, Ctr Hlth Policy Programs & Econ, Melbourne, Vic, Australia.
RP Baxter, AJ (reprint author), Univ Queensland, Sch Populat Hlth, Herston, Qld, Australia.
EM amanda_baxter@qcmhr.uq.edu.au
RI Degenhardt, Louisa/D-4515-2012; Patton, George C/B-5246-2013; Baxter,
   Amanda/E-5449-2011; Whiteford, Harvey A/A-4840-2009
OI Degenhardt, Louisa/0000-0002-8513-2218; Patton, George
   C/0000-0001-5039-8326; Baxter, Amanda/0000-0001-8198-9022; Whiteford,
   Harvey A/0000-0003-4667-6623
FU Queensland Department of Health; NH&MRC Senior Research Fellowships
FX Core funding for QCMHR is provided by the Queensland Department of
   Health. George Patton and Louisa Degenhardt are funded by NH&MRC Senior
   Research Fellowships. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abu-Saba MB, 1999, J TRAUMA STRESS, V12, P201, DOI 10.1023/A:1024766920789
   Afifi M., 2007, SMJ Singapore Medical Journal, V48, P385
   American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   Baxter AJ, 2013, PSYCHOL MED, V43, P897, DOI 10.1017/S003329171200147X
   Baxter AJ, 2011, FACTORS INFLUENCING
   Beard JR, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-83
   Bennett D, 2004, BRIT J PSYCHIAT, V185, P312, DOI 10.1192/bjp.185.4.312
   Bobak M, 2006, BRIT J PSYCHIAT, V188, P359, DOI 10.1192/bjp.188.4.359
   BRUCE ML, 1994, AM J PSYCHIAT, V151, P716
   Burns JK, 2011, EUROPEAN SCI EDITING, V37, P4
   Erskine HE, 2013, INT J EAT D IN PRESS
   Fergusson DM, 2007, BRIT J PSYCHIAT, V191, P335, DOI 10.1192/bjp.bp.107.036079
   Ferrari AJ, 2013, PSYCHOL MED, V43, P471, DOI 10.1017/S0033291712001511
   Ferrari AJ, 2011, J AFFECT DISORDERS, V134, P1, DOI 10.1016/j.jad.2010.11.007
   Gottlieb CA, 2009, LANCET, V374, P1831, DOI 10.1016/S0140-6736(09)61871-7
   Guiao I Z, 1994, Health Care Women Int, V15, P197
   Harrison G, 2001, BRIT J PSYCHIAT, V178, P506, DOI 10.1192/bjp.178.6.506
   Herrman Helen, 2010, Indian J Psychiatry, V52, pS43, DOI 10.4103/0019-5545.69207
   Hollander AC, 2007, J NERV MENT DIS, V195, P955, DOI 10.1097/NMD.0b013e318159604b
   Hollingworth SA, 2010, AUST NZ J PSYCHIAT, V44, P513, DOI 10.3109/00048670903555138
   Horton R, 2007, LANCET, V6736, P61243
   Hoyer J, 2002, J ANXIETY DISORD, V16, P113, DOI 10.1016/S0887-6185(01)00094-9
   Kessler RC, 2008, WHO WORLD MENTAL HLT
   Knudsen AK, 2010, AM J EPIDEMIOL, V172, P1306, DOI 10.1093/aje/kwq257
   KOUZIS A, 1995, SOC PSYCH PSYCH EPID, V30, P165, DOI 10.1007/BF00790655
   Kruijshaar ME, 2005, EUR J EPIDEMIOL, V20, P103, DOI 10.1007/s10654-004-1009-0
   Levy BS, 2009, ANNU REV PUBL HEALTH, V30, P123, DOI 10.1146/annurev.publhealth.031308.100147
   Lorenzo C R, 2002, Eat Weight Disord, V7, P202
   McGrath J, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-13
   Modrzejewska Renata, 2006, Psychiatr Pol, V40, P1117
   Moffitt TE, 2010, PSYCHOL MED, V40, P899, DOI 10.1017/S0033291709991036
   Moffitt TE, 2007, ARCH GEN PSYCHIAT, V64, P651, DOI 10.1001/archpsyc.64.6.651
   Mogga S, 2006, BRIT J PSYCHIAT, V189, P241, DOI 10.1192/bjp.hp.105.013417
   MURPHY JM, 1987, ARCH GEN PSYCHIAT, V44, P473
   Murray C, 1996, THE GLOBAL BURDEN OF
   Murray CJL, 2007, LANCET, V370, P109, DOI 10.1016/S0140-6736(07)61064-2
   Patel V, 2008, LANCET, V372, P1354, DOI 10.1016/S0140-6736(08)61556-1
   Patton GC, 2012, LANCET, V379, P1665, DOI 10.1016/S0140-6736(12)60203-7
   RASTAM M, 2003, EUR CHILD ADOLESC S1, V12, P78, DOI DOI 10.1007/S00787-003-1111-Y
   Reddy YGJ, 2003, ACTA PSYCHIAT SCAND, V107, P457
   Richardson AJ, 2000, PROSTAG LEUKOTR ESS, V63, P79, DOI 10.1054/plef.2000.0196
   Rose S, 1999, PSYCHOL MED, V29, P793, DOI 10.1017/S0033291799008624
   Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Schuurmans J, 2005, ACTA PSYCHIAT SCAND, V111, P420, DOI 10.1111/j.1600-0447.2005.00531.x
   Sihvola E, 2010, EARLY ONSET DEPRESSI
   Slade T, 2005, PSYCHOL MED, V35, P489, DOI 10.1017/S0033291704003708
   Spijker J, 2002, BRIT J PSYCHIAT, V181, P208, DOI 10.1192/bjp.181.3.208
   Steel Z, 2009, JAMA-J AM MED ASSOC, V302, P537, DOI 10.1001/jama.2009.1132
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   TEPLIN LA, 1990, AM J PUBLIC HEALTH, V80, P663, DOI 10.2105/AJPH.80.6.663
   The World Health Organization (WHO), 2001, WORLD HLTH REP 2001
   Van Hout HPJ, 2004, BRIT J PSYCHIAT, V185, P399, DOI 10.1192/bjp.185.5.399
   Ventevogel P, 2007, SOC PSYCH PSYCH EPID, V42, P328, DOI 10.1007/s00127-007-0161-8
   Von Korff M, 2009, GLOBAL PERSPECTIVES
   Wang JL, 2004, MED CARE, V42, P543, DOI 10.1097/01.mlr.0000128001.73998.5c
   Wang PS, 2007, WORLD PSYCHIATRY, V6, P177
   Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253
   Whiteford HA, 2012, MENTAL DISO IN PRESS
   World Health Organization, 1993, ICD 10 CLASS MENT BE
   Youngstrom E, 2005, BIOL PSYCHIAT, V58, P569, DOI 10.1016/j.biopsych.2005.04.004
NR 61
TC 67
Z9 69
U1 2
U2 38
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 24
PY 2013
VL 8
IS 6
AR e65514
DI 10.1371/journal.pone.0065514
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 182JP
UT WOS:000321738400003
PM 23826081
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Liu, SP
   Lin, CC
   Lin, HC
   Chen, YH
   Yu, HJ
AF Liu, Shih-Ping
   Lin, Ching-Chun
   Lin, Herng-Ching
   Chen, Yi-Hua
   Yu, Hong-Jeng
TI Association between Schizophrenia and Urinary Calculi: A
   Population-Based Case-Control Study
SO PLOS ONE
LA English
DT Article
ID KIDNEY-STONES; MEDICAL COMORBIDITY; NEPHROLITHIASIS; RISK; EPIDEMIOLOGY;
   MORTALITY; PREVALENCE; DISEASE; TIME
AB Background: People with schizophrenia have been demonstrated to have higher overall morbidity and all-cause mortality rates from general medical conditions. However, little attention has been given to the urinary system of people with schizophrenia. As no direct evidence has been reported demonstrating a link between schizophrenia and urinary calculi, this study utilized a population-based case-control study design to investigate the possibility of an association between schizophrenia and the occurrence of urinary calculi.
   Method: This study used data from the Taiwan Longitudinal Health Insurance Database. Cases consisted of 53,965 urinary calculi patients newly diagnosed between 2002 and 2008. In total, 269,825 controls were randomly selected and matched with the cases in terms of age and sex. Each person was traced to discern whether he had previously received a diagnosis of schizophrenia. Conditional logistic regression models were performed for the analysis.
   Results: A total of 3,119 (1.0%) subjects had been diagnosed with schizophrenia prior to the index date. This included 0.7% of the patients with urinary calculi, and 1.0% of the controls. A prior diagnosis of schizophrenia was independently associated with a 30% decrease (95% CI = 0.62-0.76) in the occurrence of urinary calculi. The reduction was even more remarkable in males (38%, 95% CI = 0.55-0.71) and in elder individuals independent of gender (48% in those aged >69,95% CI = 0.36-0.77).
   Conclusion: Our findings suggest that there is an inverse association between schizophrenia and urinary calculi. Future studies are needed to elucidate the mechanisms by which schizophrenia negatively associates with urinary calculi.
C1 [Liu, Shih-Ping; Yu, Hong-Jeng] Natl Taiwan Univ Hosp, Dept Urol, Taipei, Taiwan.
   [Lin, Ching-Chun] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Biomed Informat, Taipei, Taiwan.
   [Lin, Herng-Ching] Taipei Med Univ, Coll Publ Hlth & Nutr, Sch Hlth Care Adm, Taipei, Taiwan.
   [Chen, Yi-Hua] Taipei Med Univ, Coll Publ Hlth & Nutr, Sch Publ Hlth, Taipei, Taiwan.
   [Yu, Hong-Jeng] Far Eastern Mem Hosital, Dept Surg, Div Urol, New Taipei, Taiwan.
RP Yu, HJ (reprint author), Natl Taiwan Univ Hosp, Dept Urol, Taipei, Taiwan.
EM yhj5251@ntu.edu.tw
OI YU, HONG-JENG/0000-0003-3287-5736; LIU, SHIH-PING/0000-0002-8015-0695
CR Amato M, 2004, UROL INT, V72, P1, DOI 10.1159/000076582
   Barak Y, 2005, CANCER-AM CANCER SOC, V104, P2817, DOI 10.1002/cncr.21574
   Bonney WW, 1997, SCHIZOPHR RES, V25, P243, DOI 10.1016/S0920-9964(97)00021-2
   Borghi L, 2002, NEW ENGL J MED, V346, P77, DOI 10.1056/NEJMoa010369
   Brown S, 2000, BRIT J PSYCHIAT, V177, P212, DOI 10.1192/bjp.177.3.212
   Carney CP, 2006, J GEN INTERN MED, V21, P1133, DOI 10.1111/j.1525-1497.2006.00563.x
   Carra G, 2012, EUR ARCH PSY CLIN N, V262, P607, DOI 10.1007/s00406-012-0305-z
   Curhan GC, 2007, UROL CLIN N AM, V34, P287, DOI 10.1016/j.ucl.2007.04.003
   Curhan GC, 1996, AM J EPIDEMIOL, V143, P240
   Curhan GC, 1997, J AM SOC NEPHROL, V8, P1568
   DAngelo A, 1997, MINER ELECTROL METAB, V23, P269
   DELEON J, 1994, BIOL PSYCHIAT, V35, P408, DOI 10.1016/0006-3223(94)90008-6
   Dundas Brian, 2007, Curr Psychiatry Rep, V9, P236, DOI 10.1007/s11920-007-0025-7
   EATON WW, 1992, SCHIZOPHR RES, V6, P181, DOI 10.1016/0920-9964(92)90001-L
   Ettinger B, 1997, J UROLOGY, V158, P2069, DOI 10.1016/S0022-5347(01)68155-2
   Green AI, 2003, PSYCHIAT CLIN N AM, V26, P115, DOI 10.1016/S0193-953X(02)00014-X
   HARRIS AE, 1988, SCHIZOPHRENIA BULL, V14, P85, DOI 10.1093/schbul/14.1.85
   Jeste DV, 1996, SCHIZOPHRENIA BULL, V22, P413, DOI 10.1093/schbul/22.3.413
   JOHNSON CM, 1979, KIDNEY INT, V16, P624, DOI 10.1038/ki.1979.173
   Kato Y, 2005, UROL RES, V33, P476, DOI 10.1007/s00240-005-0511-5
   KOHRI K, 1990, BONE MINER, V8, P59, DOI 10.1016/0169-6009(91)90141-L
   Leucht S, 2007, ACTA PSYCHIAT SCAND, V116, P317, DOI 10.1111/j.1600-0447.2007.01095.x
   McGrath J, 2008, EPIDEMIOL REV, V30, P67, DOI 10.1093/epirev/mxn001
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Shiloh R, 2001, EUR PSYCHIAT, V16, P497, DOI 10.1016/S0924-9338(01)00612-5
   Stamatelou KK, 2003, KIDNEY INT, V63, P1817, DOI 10.1046/j.1523-1755.2003.00917.x
   Taylor EN, 2005, JAMA-J AM MED ASSOC, V293, P455, DOI 10.1001/jama.293.4.455
   Taylor EN, 2005, KIDNEY INT, V68, P1230, DOI 10.1111/j.1523-1755.2005.00516.x
   Terao T, 1999, AUST NZ J PSYCHIAT, V33, P769
   Walker D, 1971, J UROLOGY, V1054, P868
   Weber NS, 2009, PSYCHIAT SERV, V60, P1059, DOI 10.1176/appi.ps.60.8.1059
   YODER V, 1984, AM J PSYCHIAT, V141, P617, DOI 10.1176/ajp.141.4.617
NR 32
TC 1
Z9 1
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 7
PY 2013
VL 8
IS 3
AR e56942
DI 10.1371/journal.pone.0056942
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 136BN
UT WOS:000318334500008
PM 23505416
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Nordentoft, M
   Wahlbeck, K
   Hallgren, J
   Westman, J
   Osby, U
   Alinaghizadeh, H
   Gissler, M
   Laursen, TM
AF Nordentoft, Merete
   Wahlbeck, Kristian
   Hallgren, Jonas
   Westman, Jeanette
   Osby, Urban
   Alinaghizadeh, Hassan
   Gissler, Mika
   Laursen, Thomas Munk
TI Excess Mortality, Causes of Death and Life Expectancy in 270,770
   Patients with Recent Onset of Mental Disorders in Denmark, Finland and
   Sweden
SO PLOS ONE
LA English
DT Article
ID AUSTRALIAN PSYCHIATRIC-PATIENTS; BIPOLAR AFFECTIVE-DISORDER;
   ISCHEMIC-HEART-DISEASE; HEALTH-CARE; CARDIOVASCULAR RISK;
   PHYSICAL-ACTIVITY; FOLLOW-UP; SCHIZOPHRENIA; PEOPLE; SUICIDE
AB Background: Excess mortality among patients with severe mental disorders has not previously been investigated in detail in large complete national populations.
   Objective: To investigate the excess mortality in different diagnostic categories due to suicide and other external causes of death, and due to specific causes in connection with diseases and medical conditions.
   Methods: In longitudinal national psychiatric case registers from Denmark, Finland, and Sweden, a cohort of 270,770 recent-onset patients, who at least once during the period 2000 to 2006 were admitted due to a psychiatric disorder, were followed until death or the end of 2006. They were followed for 912,279 person years, and 28,088 deaths were analyzed. Life expectancy and standardized cause-specific mortality rates were estimated in each diagnostic group in all three countries.
   Results: The life expectancy was generally approximately 15 years shorter for women and 20 years shorter for men, compared to the general population. Mortality due to diseases and medical conditions was increased two-to three-fold, while excess mortality from external causes ranged from three-to 77-fold. Mortality due to diseases and medical conditions was generally lowest in patients with affective disorders and highest in patients with substance abuse and personality disorders, while mortality due to suicide was highest in patients with affective disorders and personality disorders, and mortality due to other external causes was highest in patients with substance abuse.
   Conclusions: These alarming figures call for action in order to prevent the high mortality.
C1 [Nordentoft, Merete] Univ Copenhagen, Fac Hlth Sci, Psychiat Ctr Copenhagen, iPSYCH, Copenhagen, Denmark.
   [Nordentoft, Merete; Wahlbeck, Kristian; Westman, Jeanette; Gissler, Mika; Laursen, Thomas Munk] Nord Res Acad Mental Hlth, Nord Sch Publ Hlth, Gothenburg, Sweden.
   [Hallgren, Jonas] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
   [Westman, Jeanette; Osby, Urban; Alinaghizadeh, Hassan] Karolinska Inst, Ctr Family Med, Care Sci & Soc, Dept Neurobiol, Stockholm, Sweden.
   [Osby, Urban] Karolinska Inst, Ctr Mol Med, Neurogenet Unit, Dept Mol Med & Surg, Stockholm, Sweden.
   [Wahlbeck, Kristian; Gissler, Mika] THL Natl Inst Hlth & Welf, Helsinki, Finland.
   [Laursen, Thomas Munk] Aarhus Univ, Natl Ctr Register Based Res, iPSYCH, Aarhus, Denmark.
RP Nordentoft, M (reprint author), Univ Copenhagen, Fac Hlth Sci, Psychiat Ctr Copenhagen, iPSYCH, Copenhagen, Denmark.
EM mn@dadlnet.dk
RI Wahlbeck, Kristian/F-8394-2011
OI Wahlbeck, Kristian/0000-0003-3754-3933; Westman,
   Jeanette/0000-0001-8701-4226; Laursen, Thomas Munk/0000-0001-6934-1784;
   Alinaghizadeh, Hassan/0000-0002-9455-0753
FU Nordic Council of Ministers; Lundbeck Foundation [R155-2014-1724];
   Medical Research Council [MR/K006525/1]
FX The study was supported by Nordic Council of Ministers. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bobes J, 2010, SCHIZOPHR RES, V119, P101, DOI 10.1016/j.schres.2010.02.1030
   Brown S, 2000, BRIT J PSYCHIAT, V177, P212, DOI 10.1192/bjp.177.3.212
   Brown S, 1999, PSYCHOL MED, V29, P697, DOI 10.1017/S0033291798008186
   Brown S, 1997, BRIT J PSYCHIAT, V171, P502, DOI 10.1192/bjp.171.6.502
   Brown S, 2011, SOC PSYCHIAT PSYCHIA
   Brown S, 2010, BRIT J PSYCHIAT, V196, P116, DOI 10.1192/bjp.bp.109.067512
   Compton MT, 2006, HARVARD REV PSYCHIAT, V14, P212, DOI 10.1080/10673220600889256
   Cuijpers P, 2002, J AFFECT DISORDERS, V72, P227, DOI 10.1016/S0165-0327(01)00413-X
   Daumit GL, 2008, SCHIZOPHR RES, V105, P175, DOI 10.1016/j.schres.2008.07.006
   Daumit GL, 2005, J NERV MENT DIS, V193, P641, DOI 10.1097/01.nmd.0000180737.85895.60
   De Hert M, 2009, EUR PSYCHIAT, V24, P412, DOI 10.1016/j.eurpsy.2009.01.005
   De Hert M, 2001, SCHIZOPHR RES, V47, P127, DOI 10.1016/S0920-9964(00)00003-7
   De Hert M, 2011, WORLD PSYCHIATRY, V10, P52
   Dixon LB, 2010, SCHIZOPHRENIA BULL, V36, P48, DOI 10.1093/schbul/sbp115
   Druss BG, 2011, MED CARE, V49, P599, DOI 10.1097/MLR.0b013e31820bf86e
   Dutta R, 2010, SCHIZOPHR RES
   Green AI, 2000, GEN HOSP PSYCHIAT, V22, P224, DOI 10.1016/S0163-8343(00)00081-5
   Hansen T, 2011, BIOL PSYCHIAT
   Hoang U, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5422
   Inskip HM, 1998, BRIT J PSYCHIAT, V172, P35, DOI 10.1192/bjp.172.1.35
   Joukamaa M, 2001, BRIT J PSYCHIAT, V179, P498, DOI 10.1192/bjp.179.6.498
   Juel K, 1999, DAN MED BULL, V46, P354
   KESKIMAKI I, 1991, INT J HLTH SCI, V2, P15
   Kisely S, 2005, BRIT J PSYCHIAT, V187, P552, DOI 10.1192/bjp.187.6.552
   Kisely S, 2007, CAN MED ASSOC J, V176, P779, DOI 10.1503/cmaj.060482
   Kisely S, 2009, BRIT J PSYCHIAT, V195, P545, DOI 10.1192/bjp.bp.109.067082
   Lahti RA, 2001, FORENSIC SCI INT, V115, P15, DOI 10.1016/S0379-0738(00)00300-5
   Laursen TM, 2007, J CLIN PSYCHIAT, V68, P899, DOI 10.4088/JCP.v68n0612
   Laursen TM, 2011, SCHIZOPHR RES, V131, P101, DOI 10.1016/j.schres.2011.06.008
   Laursen TM, 2011, J PSYCHIATR RES, V45, P29, DOI 10.1016/j.jpsychires.2010.04.027
   Laursen TM, 2009, ARCH GEN PSYCHIAT, V66, P713, DOI 10.1001/archgenpsychiatry.2009.61
   Lawrence D, 2000, ACTA PSYCHIAT SCAND, V101, P382, DOI 10.1034/j.1600-0447.2000.101005382.x
   Lawrence D, 2000, SOC PSYCH PSYCH EPID, V35, P341, DOI 10.1007/s001270050248
   Lawrence D, 2010, CAN J PSYCHIAT, V55, P752, DOI 10.1177/070674371005501202
   Lawrence D, 2010, J PSYCHOPHARMACOL, V24, P61, DOI 10.1177/1359786810382058
   Lawrence DM, 2003, BRIT J PSYCHIAT, V182, P31, DOI 10.1192/bjp.182.1.31
   Lindahl ML, 2010, NORD J PSYCHIAT, V64, P372, DOI 10.3109/08039481003710204
   Mors O, 2011, SCAND J PUBLIC HEALT, V39, P54, DOI 10.1177/1403494810395825
   Newcomer John W, 2007, J Clin Psychiatry, V68, pe17
   NOMESCO, 2009, HLTH STAT NORD COUNT
   Nordentoft M, 2004, BRIT MED J, V329, P261, DOI 10.1136/bmj.38133.622488.63
   Nordentoft M, 2011, ARCH GEN PSYCHIAT, V68, P1058, DOI 10.1001/archgenpsychiatry.2011.113
   Osborn DPJ, 2007, SOC PSYCH PSYCH EPID, V42, P787, DOI 10.1007/s00127-007-0247-3
   Osborn DPJ, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-61
   Osby U, 2000, SCHIZOPHR RES, V45, P21, DOI 10.1016/S0920-9964(99)00191-7
   Osby U, 2001, ARCH GEN PSYCHIAT, V58, P844, DOI 10.1001/archpsyc.58.9.844
   Palmer BA, 2005, ARCH GEN PSYCHIAT, V62, P247, DOI 10.1001/archpsyc.62.3.247
   Qin P, 2005, ARCH GEN PSYCHIAT, V62, P427, DOI 10.1001/archpsyc.62.4.427
   Rantanen H, 2009, SOC PSYCH PSYCH EPID, V44, P135, DOI 10.1007/s00127-008-0414-1
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Socialstyrelsen Wellfare NboHa, 2009, KVAL INN PAT UTSKR F, P1997
   Wahlbeck K, 2011, BR J PSYCHIAT
   World Health Organization, 2005, MENT HLTH FAC CHALL
NR 53
TC 209
Z9 211
U1 4
U2 45
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 25
PY 2013
VL 8
IS 1
AR e55176
DI 10.1371/journal.pone.0055176
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093RV
UT WOS:000315210400072
PM 23372832
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Chang, CK
   Hayes, RD
   Perera, G
   Broadbent, MTM
   Fernandes, AC
   Lee, WE
   Hotopf, M
   Stewart, R
AF Chang, Chin-Kuo
   Hayes, Richard D.
   Perera, Gayan
   Broadbent, Mathew T. M.
   Fernandes, Andrea C.
   Lee, William E.
   Hotopf, Mathew
   Stewart, Robert
TI Life Expectancy at Birth for People with Serious Mental Illness and
   Other Major Disorders from a Secondary Mental Health Care Case Register
   in London
SO PLOS ONE
LA English
DT Article
ID PRACTICE RESEARCH DATABASE; ALL-CAUSE MORTALITY; PHYSICAL HEALTH;
   PREMATURE MORTALITY; MEDICAL ILLNESSES; BIPOLAR DISORDER; EXCESS
   MORTALITY; SCHIZOPHRENIA; SUICIDE; COHORT
AB Objective: Despite improving healthcare, the gap in mortality between people with serious mental illness (SMI) and general population persists, especially for younger age groups. The electronic database from a large and comprehensive secondary mental healthcare provider in London was utilized to assess the impact of SMI diagnoses on life expectancy at birth.
   Method: People who were diagnosed with SMI (schizophrenia, schizoaffective disorder, bipolar disorder), substance use disorder, and depressive episode/disorder before the end of 2009 and under active review by the South London and Maudsley NHS Foundation Trust (SLAM) in southeast London during 2007-09 comprised the sample, retrieved by the SLAM Case Register Interactive Search (CRIS) system. We estimated life expectancy at birth for people with SMI and each diagnosis, from national mortality returns between 2007-09, using a life table method.
   Results: A total of 31,719 eligible people, aged 15 years or older, with SMI were analyzed. Among them, 1,370 died during 2007-09. Compared to national figures, all disorders were associated with substantially lower life expectancy: 8.0 to 14.6 life years lost for men and 9.8 to 17.5 life years lost for women. Highest reductions were found for men with schizophrenia (14.6 years lost) and women with schizoaffective disorders (17.5 years lost).
   Conclusion: The impact of serious mental illness on life expectancy is marked and generally higher than similarly calculated impacts of well-recognised adverse exposures such as smoking, diabetes and obesity. Strategies to identify and prevent causes of premature death are urgently required.
C1 [Chang, Chin-Kuo; Lee, William E.; Hotopf, Mathew] Kings Coll London, Inst Psychiat, Acad Dept Psychol Med, London WC2R 2LS, England.
   [Broadbent, Mathew T. M.] S London & Maudsley NHS Fdn Trust, London, England.
RP Chang, CK (reprint author), Kings Coll London, Inst Psychiat, Acad Dept Psychol Med, London WC2R 2LS, England.
EM chin-kuo.chang@kcl.ac.uk
RI Stewart, Robert/B-1667-2010; Hayes, Richard/D-2382-2010; Lee,
   William/B-5836-2011; Chang, Chin-Kuo/E-4991-2010
OI Stewart, Robert/0000-0002-4435-6397; Lee, William/0000-0002-0607-038X;
   Chang, Chin-Kuo/0000-0002-8338-7196; Hotopf,
   Matthew/0000-0002-3980-4466; Hayes, Richard/0000-0003-4453-244X
FU UK National Institute for Health Research; Guy's Trust; St Thomas'
   Trust; South London Special Trust; Maudsley Special Trust; National
   Institute for Health Research (NIHR) Specialist Biomedical Research
   Centre for Mental Health at the South London; Maudsley NHS Foundation
   Trust; Institute of Psychiatry, King's College London; UK Medical
   Research Council; Medical Research Council [G0601720]
FX The development of the SLAM BRC Case Register was funded by two Capital
   Awards from the UK National Institute for Health Research and is further
   supported through the BRC Nucleus funded jointly by the Guy's and St
   Thomas' Trustees and South London and Maudsley Special Trustees. C-KC,
   RH, AF, MB, MH and RS are funded by the National Institute for Health
   Research (NIHR) Specialist Biomedical Research Centre for Mental Health
   at the South London and Maudsley NHS Foundation Trust and Institute of
   Psychiatry, King's College London. WL is funded by the UK Medical
   Research Council. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Auquier P, 2006, PHARMACOEPIDEM DR S, V15, P873, DOI 10.1002/pds.1325
   Baxter DN, 1996, BRIT J PSYCHIAT, V168, P772, DOI 10.1192/bjp.168.6.772
   Brown S, 2000, BRIT J PSYCHIAT, V177, P212, DOI 10.1192/bjp.177.3.212
   Brown S, 1999, PSYCHOL MED, V29, P697, DOI 10.1017/S0033291798008186
   CALDWELL CB, 1990, SCHIZOPHRENIA BULL, V16, P571, DOI 10.1093/schbul/16.4.571
   Carter KN, 2010, NEW ZEAL MED J, V123, P13
   Chang CK, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-77
   Chiang CL, 1984, LIFE TABLE ITS APPL
   Chwastiak LA, 2009, LANCET, V374, P590, DOI 10.1016/S0140-6736(09)61072-2
   Clarke CA, 2010, SOC SCI MED, V70, P1373, DOI 10.1016/j.socscimed.2010.01.003
   Colton Craig W, 2006, Prev Chronic Dis, V3, pA42
   Connolly M, 2005, ADV PSYCHIAT TREATME, V11, P125, DOI [DOI 10.1192/APT.11.2.125, 10.1192/apt.11.2.125]
   Danaei G, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000248
   De Hert M, 2009, EUR PSYCHIAT, V24, P412, DOI 10.1016/j.eurpsy.2009.01.005
   Dembling BP, 1999, PSYCHIATR SERV, V50, P1036, DOI 10.1176/ps.50.8.1036
   Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE
   Dutta R, 2007, PSYCHOL MED, V37, P839, DOI 10.1017/S0033291707000347
   Fagiolini A, 2009, J CLIN PSYCHIAT, V70, P22, DOI 10.4088/JCP.7075su1c.04
   Gray R, 2009, INT J MENT HEALTH NU, V18, P299, DOI 10.1111/j.1447-0349.2009.00640.x
   *GREAT LOND AUTH I, 2010, LIF EXP BIRTH 2007 0
   Hannerz H, 2001, PUBLIC HEALTH, V115, P328
   Harris EC, 1998, BRIT J PSYCHIAT, V173, P11, DOI 10.1192/bjp.173.1.11
   McGirr A, 2008, SCHIZOPHR RES, V98, P217, DOI 10.1016/j.schres.2007.09.009
   McGrath J, 2008, EPIDEMIOL REV, V30, P67, DOI 10.1093/epirev/mxn001
   *METH GROUP OFF NA, 2003, NAT STAT METH SER, V33
   Montejo AL, 2010, EUR PSYCHIAT, V25, pS3, DOI 10.1016/S0924-9338(10)71699-0
   Newcomer JW, 2007, JAMA-J AM MED ASSOC, V298, P1794, DOI 10.1001/jama.298.15.1794
   Office for National Statistics, 2009, MORT STAT DEATHS REG
   Office of National Statistics, 2009, LIF EXP BIRTH REM HI
   Osborn D, 2008, SCHIZOPHR RES, V99, P134, DOI 10.1016/j.schres.2007.11.025
   Osborn DPJ, 2007, ARCH GEN PSYCHIAT, V64, P242, DOI 10.1001/archpsyc.64.2.242
   Osby U, 2000, BRIT MED J, V321, P483, DOI 10.1136/bmj.321.7259.483
   Ozasa K, 2008, J EPIDEMIOL, V18, P111, DOI 10.2188/jea.JE2007416
   Piatt EE, 2010, PSYCHIAT SERV, V61, P663, DOI 10.1176/ps.2010.61.7.663
   POL LG, 2010, DEMOGRAPHY HLTH HLTH
   Robson D, 2007, INT J NURS STUD, V44, P457, DOI 10.1016/j.ijnurstu.2006.07.013
   Roshanaei-Moghaddam B, 2009, PSYCHIAT SERV, V60, P147, DOI 10.1176/appi.ps.60.2.147
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Sikdar KC, 2010, QUAL LIFE RES, V19, P781, DOI 10.1007/s11136-010-9641-5
   Smith S, 2007, EUR PSYCHIAT, V22, P413, DOI 10.1016/j.eurpsy.2007.07.002
   Stewart R, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-51
   Tamakoshi A, 2010, J EPIDEMIOL, V20, P370, DOI 10.2188/jea.JE20100017
   Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4
NR 43
TC 253
Z9 254
U1 1
U2 28
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 18
PY 2011
VL 6
IS 5
AR e19590
DI 10.1371/journal.pone.0019590
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 765PE
UT WOS:000290720200017
PM 21611123
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Saha, S
   Scott, J
   Varghese, D
   McGrath, J
AF Saha, Sukanta
   Scott, James
   Varghese, Daniel
   McGrath, John
TI The Association between Physical Health and Delusional-Like Experiences:
   A General Population Study
SO PLOS ONE
LA English
DT Article
ID REPORTED PSYCHOTIC SYMPTOMS; 2007 NATIONAL-SURVEY; QUALITY-OF-LIFE;
   RHEUMATOID-ARTHRITIS; HEARING IMPAIRMENT; MENTAL-HEALTH; YOUNG-ADULTS;
   PREVALENCE; COMMUNITY; DISORDER
AB Objective: Delusional-like experiences (DLE) are prevalent in the community. Recent community based studies have found that DLE are more common in those with depression and anxiety disorders, and in those with subclinical symptoms of depression and anxiety. Chronic physical disorders are associated with comorbid depression and anxiety; however, there is a lack of evidence about the association of DLE with common physical conditions. The aim of this study was to explore associations between the common physical disorders and DLE using a large population sample.
   Methods: Subjects were drawn from the Australian National Survey of Mental Health and Wellbeing 2007, a national household survey of 8841 residents aged between 16 and 85 years. The presence of DLE, selected common physical disorders and symptoms were assessed using a modified World Mental Health Composite International Diagnostic Interview (CIDI) schedule. We examined the relationship between DLE, and physical health-related variables using logistic regression, with adjustments for potential confounding factors.
   Results: Of the 8771, 776 (8.4%) subjects positively endorsed one or more DLE. Of the six physical disorders examined, only diabetes and arthritis were significantly associated with the endorsement of DLE. Of the seven broad physical symptoms explored, only hearing problems were consistently associated with DLE.
   Conclusion: Delusional-like experiences are common in the Australian community, and are associated with selected chronic physical disorders and with impaired hearing. The direction of causality between these variables warrants closer research scrutiny.
C1 [Saha, Sukanta; Scott, James; McGrath, John] Queensland Ctr Mental Hlth Res, Pk Ctr Mental Hlth, Wacol, Qld, Australia.
   [Scott, James] Royal Brisbane & Womens Hosp, Hertson, Qld, Australia.
   [Scott, James; Varghese, Daniel; McGrath, John] Univ Queensland, Discipline Psychiat, Sch Med, St Lucia, Qld, Australia.
   [Scott, James] Univ Queensland, Clin Res Ctr, Herston, Qld, Australia.
   [Varghese, Daniel] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia.
   [McGrath, John] Univ Queensland, Queensland Brain Inst, St Lucia, Qld, Australia.
RP Saha, S (reprint author), Queensland Ctr Mental Hlth Res, Pk Ctr Mental Hlth, Wacol, Qld, Australia.
EM sukanta_saha@qcmhr.uq.edu.au
RI McGrath, John J/G-5493-2010; Scott, James Graham/D-5900-2012
OI McGrath, John J/0000-0002-4792-6068; Scott, James
   Graham/0000-0002-0744-0688
CR AN AB, 2004, P 27 ANN SAS US GROU
   *AUSTR BUR STAT, 1998, MENT HLTH WELB PROF
   *AUSTR BUR STAT, 2008, MENT HLTH WELB SUMM
   Australian Bureau of Statistics, 2007, NAT SURV MENT HLTH W
   COOPER AF, 1974, LANCET, V2, P851
   COOPER AF, 1976, J PSYCHOSOM RES, V20, P97, DOI 10.1016/0022-3999(76)90035-0
   CREED F, 1990, ANN RHEUM DIS, V49, P808, DOI 10.1136/ard.49.10.808
   Dickens C, 2002, PSYCHOSOM MED, V64, P52, DOI 10.1097/00006842-200201000-00008
   Gendelman N, 2009, DIABETES CARE, V32, P575, DOI 10.2337/dc08-1835
   Hanssen M, 2005, BRIT J CLIN PSYCHOL, V44, P181, DOI 10.1348/014466505X29611
   Harris Michael D, 2003, Curr Diab Rep, V3, P49, DOI 10.1007/s11892-003-0053-6
   Hislop AL, 2008, DIABETIC MED, V25, P91, DOI 10.1111/j.1464-5491.2007.02310.x
   Houssien DA, 1997, BRIT J RHEUMATOL, V36, P69
   Johns LC, 2004, BRIT J PSYCHIAT, V185, P298, DOI 10.1192/bjp.185.4.298
   Katon WJ, 2008, AM J MED, V121, P8, DOI 10.1016/j.amjmed.2008.09.008
   KELLEHER I, 2010, PSYCHOL MED, P1
   Leucht S, 2007, ACTA PSYCHIAT SCAND, V116, P317, DOI 10.1111/j.1600-0447.2007.01095.x
   Moffitt TE, 2010, PSYCHOL MED, V40, P899, DOI 10.1017/S0033291709991036
   MURPHY S, 1988, BRIT J RHEUMATOL, V27, P357
   Pollard L, 2005, CLIN EXP RHEUMATOL, V23, pS43
   Poulton R, 2000, ARCH GEN PSYCHIAT, V57, P1053, DOI 10.1001/archpsyc.57.11.1053
   Rust K F, 1996, Stat Methods Med Res, V5, P283, DOI 10.1177/096228029600500305
   SAHA S, 2010, SCHIZOPHR R IN PRESS
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Scott J, 2008, ACTA PSYCHIAT SCAND, V118, P230, DOI 10.1111/j.1600-0447.2008.01214.x
   Scott J, 2006, PSYCHOL MED, V36, P231, DOI 10.1017/S0033291705006392
   Scott J, 2007, BRIT J PSYCHIAT, V190, P339, DOI 10.1192/bjp.bp.106.026708
   Shevlin M, 2008, SCHIZOPHRENIA BULL, V34, P193, DOI 10.1093/schbul/sbm069
   Slade T, 2009, AUST NZ J PSYCHIAT, V43, P594, DOI 10.1080/00048670902970882
   Spauwen J, 2006, BRIT J PSYCHIAT, V188, P527, DOI 10.1192/bjp.bp.105.011346
   Stefanis N, 2006, SCHIZOPHR RES, V85, P266, DOI 10.1016/j.schres.2006.03.036
   Susser E, 2010, PSYCHOL MED, V40, P895, DOI 10.1017/S0033291709991504
   Teesson M, 2009, AUST NZ J PSYCHIAT, V43, P606, DOI 10.1080/00048670902970908
   Thewissen V, 2005, SCHIZOPHR RES, V76, P99, DOI 10.1016/j.schres.2004.10.013
   van Os J, 2000, SCHIZOPHR RES, V45, P11, DOI 10.1016/S0920-9964(99)00224-8
   van Os J, 2009, PSYCHOL MED, V39, P179, DOI 10.1017/S0033291708003814
   VANDERWERF M, 2010, SCHIZOPHR RES, V17, P417
   VARGHESE D, 2009, SCHIZOPHR B
   VARGHESE D, 2009, SCHIZOPHR B IN PRESS
   Varghese D, 2008, AUST NZ J PSYCHIAT, V42, P505, DOI 10.1080/00048670802050595
   von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43
NR 41
TC 24
Z9 24
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 25
PY 2011
VL 6
IS 4
AR e18566
DI 10.1371/journal.pone.0018566
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 756MU
UT WOS:000290016800015
PM 21541344
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

EF